Identifying Mechanisms of Drug Tolerance in EGFR Mutant Lung Cancer by Hu, Bomiao
Yale University 
EliScholar – A Digital Platform for Scholarly Publishing at Yale 
Yale Graduate School of Arts and Sciences Dissertations 
Spring 2021 
Identifying Mechanisms of Drug Tolerance in EGFR Mutant Lung 
Cancer 
Bomiao Hu 
Yale University Graduate School of Arts and Sciences, hubomiao2008@gmail.com 
Follow this and additional works at: https://elischolar.library.yale.edu/gsas_dissertations 
Recommended Citation 
Hu, Bomiao, "Identifying Mechanisms of Drug Tolerance in EGFR Mutant Lung Cancer" (2021). Yale 
Graduate School of Arts and Sciences Dissertations. 62. 
https://elischolar.library.yale.edu/gsas_dissertations/62 
This Dissertation is brought to you for free and open access by EliScholar – A Digital Platform for Scholarly 
Publishing at Yale. It has been accepted for inclusion in Yale Graduate School of Arts and Sciences Dissertations 
by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more 
information, please contact elischolar@yale.edu. 
I  
Abstract 






The majority of EGFR mutant lung adenocarcinomas respond well to EGFR tyrosine kinase 
inhibitors (TKIs). However, most of these responses are partial with drug tolerant residual 
disease remaining even at the time of maximal response. This residual disease serves as a 
reservoir for the emergence of acquired resistance and tumor relapse, which inevitably occurs in 
patients treated with TKIs. It is thus critical to understand the biology of residual tumor cells and 
find out the mechanisms that underlie drug tolerance. Knowledge of such mechanisms could 
lead to the identification of potential strategies to forestall the emergence of drug resistance.   
Studies of residual disease have been hampered by the difficulty of studying these persister 
cells in patient specimens and most studies to date have relied on analysis of established cell 
lines in culture. To investigate the cellular and molecular properties of residual tumor cells in 
vivo, we leveraged patient-derived models of EGFR mutant lung cancer. Three EGFR mutant 
PDXs were treated with the third-generation TKI osimertinib. Tumors regressed in all cases but 
measurable residual tumor remained in 2 out of the 3 PDXs even after 6 weeks of osimertinib 
treatment. Whole-exome sequencing (WES) of the untreated PDXs compared to the residual 
tumors revealed an unchanged mutational landscape between the samples, indicating that 
genetic mechanisms did not account for drug tolerance. Bulk RNA-sequencing, however, 
demonstrated extensive transcriptional changes between the untreated PDX and residual 
disease. In one of the PDXs, we identified upregulation of the neuroendocrine lineage 
transcription factor ASCL1 in residual disease compared to untreated tumors. Using single-cell 
II  
RNA-sequencing we found a pre-existing ASCL1hi tumor cell population in untreated tumors, 
suggesting that these cells which possessed drug tolerant properties were selected for during 
drug treatment. Depending on the cell line examined, expression of ASCL1 in human mutant 
EGFR lung cancer cell lines gave rise to persister clones following osimertinib treatment. This 
result demonstrated functionally that ASCL1 could lead to TKI tolerance and that whether it did 
this depended on the cellular context. Further gene expression profiling of ASCL1-transfected 
cell lines identified an ASCL1-induced epidermal-to-mesenchymal transition (EMT) signature 
that potentially resulted in tolerance to osimertinib. Our studies provide insights into the role of 
the neuroendocrine factor ASCL1 as a potential driver of drug tolerance in mutant EGFR lung 
cancer and ongoing work is focused on identifying the mechanisms underlying the cellular 
context specificity of ASCL1-mediated EMT. 
In addition to PDX models, we also performed complementary studies on TKI tolerance in a 
genetically-engineered mouse model (GEMM) of mutant EGFR-driven lung adenocarcinoma. To 
identify and isolate drug tolerant persisters, we developed a transgenic mouse model in which 
mutant EGFR-expressing lung epithelial cells were labelled with a fluorescent marker, mKate. 
Using this model, we found that tumor-bearing mice responded almost completely to osimertinib 
and the number of mKate+ cells was decreased in response to TKI treatment and plateaued 
after 4 weeks of treatment. Targeted deep sequencing of the mutant EGFR transgene did not 
show enrichment of any resistance conferring mutations in mKate+ cells following TKI 
treatment, indicating that on-target EGFR mutations did not contribute to TKI tolerance in the 
GEMM. In contrast, RNA sequencing of DTPs sorted from this model revealed deregulation of 
metabolic and developmental pathways that could play a role in drug tolerance. 
In summary we have established and characterized state-of-the-art in vivo models to study 
drug tolerance and unveiled new potential mechanisms of TKI tolerance which serve as the 
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CHAPTER 1: LITERATURE REVIEW 
Lung Cancer 
Statistics 
Lung cancer is currently one of the most commonly diagnosed cancers and the leading 
cause of cancer-related death in the US [1]. In 2021, there are estimated to be more than 230K 
new cases and 130K deaths from lung cancer in the US. The incidence of lung cancer has been 
steadily reduced by 2% per year since mid-2000s and the death rates have been decreased by 
54% in men and 30% in women compared to their respective historical highest rates, which is 
partially due to public efforts to decrease cigarette smoking and improved screening and 
treatment options including targeted therapy [1, 2]. However, despite all these improvements, 
the overall 5-year survival rate for lung cancer is only 21%, much below the average rates for all 
cancer types taken together [1]. Most of the lung cancer cases (83%) are diagnosed at an 
advanced stage, with regional or distant metastasis, which negatively impacts treatment efficacy 
and prognosis.   
 
Histological Classifications 
Lung cancer is collection of multiple diseases. Based on the histological features lung 
cancer is categorized into small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC) and the latter can be further divided into three groups: lung adenocarcinoma (LUAD), 
lung squamous cell carcinoma and large cell lung carcinoma [3]. The incidence rates for each 
subtype are illustrated in Figure 1.1. Lung adenocarcinoma is by far the most common 
histological subtype of lung cancer, accounting for 40% of all lung cancer cases, usually arising 
in the lung periphery close to terminal bronchioles and alveoli and shows features of glandular 
differentiation. On the other hand, squamous carcinoma is localized more centrally in the lungs 
near the bronchus and characterized by keratinization [3]. Small cell lung cancer is distinct from 
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the other cancer types in that it is thought to arise from neuroendocrine (NE) cells of the lungs 
and show positivity for NE marker staining such as chromogranin A and synaptophysin. 
  
 
Driver Mutations in Lung Adenocarcinoma 
Studies of the genetics and biology of LUAD have brought tremendous insights into the 
understanding of this disease. Various driver mutations have been identified and the functions 
of these mutated oncogenes have been elucidated and translated into improvements of clinical 
practice [4]. The most commonly mutated oncogene in LUAD is KRAS, with mutations occurring 
in 30% of all LUAD cases (Figure 1.2). These mutations lock KRAS in a GTP-bound active 
state and prevent GTP hydrolysis [5]. Therefore, the mutant form of KRAS is able to transduce 
constitutive downstream growth signals, leading to uncontrollable cell proliferation. The second 
most common oncogenic mutations occur in EGFR and the mutated forms are found in 10-15% 
of LUADs in Caucasians and in even higher incident rates in East Asians (Figure 1.2). The 
majority of these LUAD-associated EGFR mutations fall into two different locations in exons 
encoding the kinase domain of EGFR: one is single nucleotide substitution in exon 21, leading 
to a leucine-to-arginine transition at codon 858 (L858R); the other is a set of short in-frame 
deletions in exon 19, resulting in a loss of 4-6 amino acids in the N-lobe of EGFR kinase domain 
(del19). 
Figure 1.1 Histological classification of lung cancer, adapted from [3] 
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Structural analyses of these EGFR mutants have determined the biochemical 
consequences of these alterations. The L858R mutation resides in the activation loop of EGFR 
kinase domain and this amino acid substitution destabilizes its inactive conformation [6] 
whereas exon 19 deletion mutations are in proximity to the αC helix and in the truncated 
mutants αC helix is pulled towards the catalytic site, thus stabilizing the active conformation [7]. 
Both forms of the EGFR mutations result in constitutive activation of the EGFR kinase and 
uncontrolled transduction of growth signals, which is similar to the consequences of KRAS 
mutations identified in LUAD. 
Beside KRAS and EGFR mutations, other less common oncogenic driver mutations have 
been gradually identified in recent years to fill in the mutational spectrum of LUAD (Figure 1.2), 
including BRAF V600E mutation, ALK translocation, ROS1 rearrangement etc. It is worth noting 
that all of these mutated oncogenes are centered at RTK-MAPK signaling pathways, 
highlighting the importance of these pathways in the growth and survival of LUAD. Many of 
these oncogenic drivers are druggable targets and targeted therapies have been approved or in 
clinical trials [8-11]. 
  
 
Treatments for Non-Small Cell Lung Cancer 
Surgery 
Figure 1.2 Driver mutations in LUAD, adapted from [4] 
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Surgery can be a good option for patients with overall good health and early-stage NSCLC 
[12]. Since the lesions are usually local and cancer cells are less aggressive, removing the 
tumor area all together provides the best chance for cure. For diseases in advanced stages, 
lesions cannot be completely removed through surgery and therapeutic agents are thus 
necessary for controlling the disease progression. In rare cases where tumor cells form single 
distant metastasis (for example, in the brain) and tumors in the lungs are manageable, surgery 
can be used to resect metastatic lesions, followed by treatment of cancers in primary sites. 
Patients usually receive adjuvant chemotherapy to eliminate any tumor cells left over and to 
reduce recurrence. Neoadjuvant therapy is also used under certain scenario to reduce tumor 
burden and improve the outcome of subsequent surgical procedures. 
 
Chemotherapy 
Chemotherapy is a common therapeutic option for NSCLC in general and can be used 
either alone or in combination with other types of therapies. It historically has been one of the 
major treatment options for patients where no driver mutations are identified or targeted 
therapies are not available (for example, cancers driven by mutant KRAS) and now is frequently 
used in combination with immunotherapies [12].  
Chemotherapy drugs like platinum-based drugs and taxanes are cytotoxic reagents that 
interfere with DNA synthesis or microtubule functions, both of which are critical biological 
processes for rapidly-proliferating cells including cancer cells. Due to the lack of specificity 
against malignant cells, chemotherapy agents can cause various side effects on multiple organs 
and systems that require constant cell proliferation and renewal, such as the digestive and 




In recent years, immune checkpoint inhibitors (ICIs) have become one of the main classes 
of drugs used to treat NSCLC. Tumor microenvironment is usually immunosuppressive and the 
normal cytotoxic functions of T cells are silenced by immune checkpoint proteins mostly 
expressed on surface of tumor cells. The idea of this drug family is to activate immune system 
to target cancer cells by blocking the inhibitory interactions between checkpoint receptors and 
ligands expressed in immune cells and tumor cells respectively. The major checkpoint pathways 
involved in the context of cancer are mediated by PD1 and CTLA4, which are the drug targets 
for immune checkpoint inhibitors [13]. 
Three classes of ICIs targeting PD1, PD-L1 or CTLA4 have been approved to treat patients 
with advanced NSCLC. Despite the fact that a proportion of patients exhibit durable responses 
to ICI treatment and improved overall survival as compared with chemotherapy, a large number 
of patients do not show objective response at all and the determinants of response to 
immunotherapy in NSCLC are still under investigation. Some retrospective studies suggest that 
patients with higher tumor mutational burden might benefit more from immunotherapy as 
nonsynonymous somatic mutations tend to produce more neoantigens that facilitate recognition 
of tumor cells by immune system [14, 15]. 
Similar to other therapies for NSCLC, patient develop acquired resistance to ICIs as well, 
which may arise through different mechanisms [13]. One prominent mechanism of resistance to 
immunotherapy is impaired antigen presentation in tumor cells, mainly through loss of functional 
β2-microglobulin, which results in defective MHC I molecules [16, 17]. Besides antigen 
presentation deficiency, other tumor cell intrinsic signaling pathways and dysfunction of T-cells 
are also implicated in driving ICI resistance [18]. 
 
Targeted Therapy 
During the past few decades, genetic profiling of patient tumors has identified subgroups of 
patients with genetic abnormalities that create vulnerabilities to drugs targeting certain gene 
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products [8-11, 19, 20]. These genetic alterations occur in certain oncogenes and cancers 
driven by these mutants become dependent on the activity of the oncogenes. These oncogenic 
drivers thus serve as drug targets. Unlike chemotherapy, the action of the targeted therapy is 
usually more restricted to cancer cells. Therefore, targeted therapy usually shows fewer side 
effects and higher efficacy compared to traditional chemotherapy when given systemically to 
patients whose tumors harbor the relevant drug targets [20]. 
Many oncogenic drivers identified in LUAD, the most common subtype of NSCLC, are 
druggable (Figure 1.2). Besides EGFR, which stands out as the most frequently mutated 
targetable driver oncogene, other oncogenic drivers including BRAF, ALK, ROS1 etc harbor 
activating mutations as well, which render the cancer cells dependent on the constitutive activity 
of these oncogenic mutants. Indeed, clinical trials for the kinase inhibitors hitting these targets 
have shown promising outcomes in selected patient populations [8-11, 19, 20] and a number of 
targeted drugs have been approved as first-line therapy for LUAD patients harboring these 
activating mutations. 
Nonetheless, as with all the other cancer treatments, acquired resistance to targeted 
therapy is inevitable in lung cancer patients [21]. Mechanisms of resistance generally fall into 
two categories: on-target and off-target. On-target resistance is caused by secondary mutations 
in the original drug targets. The resistance conferring mutations are able to reduce the efficiency 
of drug binding and lead to reactivation of the oncogenic drivers through changing the affinity of 
the kinase for ATP or creating stearic hindrance [22, 23]. Examples of on-target mechanisms 
include the EGFR T790M mutation found in patients receiving first-gen EGFR TKIs and the 
EGFR C797S found in patients treated with third-gen EGFR TKI osimertinib [24-27]. Off-target 
resistance may result from activation of alternative signaling pathways that bypass the primary 
drug targets, such as MET and ERBB2 amplification identified in TKI-treated EGFR mutant lung 
cancer patients [21, 28], or transition to another cell lineage that no longer depends on the 
7 
original oncogenes for survival, such as SCLC transformation and epidermal-to-mesenchymal 
transition (EMT) driving acquired resistance to EGFR TKIs [29]. 
 
EGFR TKI Therapies in Mutant EGFR Lung Cancer 
Since LUADs driven by EGFR mutants are addicted to the constitutive signaling activity of 
EGFR pathway, lung tumor cells harboring EGFR activating mutations become sensitive to 
EGFR TKIs, which lead to clinical trials and official approval of EGFR TKIs as first-line therapy 
for EGFR-driven lung cancer [19, 20]. The schema shown in Figure 1.3A indicates the EGFR 
TKI therapies that a patient would receive after being diagnosed with mutant EGFR lung cancer. 
Initially, these patients have been treated with 1st or 2nd gen TKIs for about a year until they 
acquired resistance to these drugs. The mechanisms of resistance to 1st and 2nd gen TKIs were 
well studied (Figure 1.3B): the most frequent mechanism is secondary gatekeeper mutation 
T790M in active center of EGFR kinase domain, which results in an increase in the binding 
affinity for natural substrate ATP, outcompeting the drugs from their binding pocket [22]. Other 
less common resistant mechanisms include activation of bypass signaling molecules in other 
RTK pathways such as MET/ERBB2 gene amplification and PI3K activating mutations, as well 
as histological transformation and phenotypic transition such as SCLC transformation and EMT 
[30]. 
To overcome T790M-mediated acquired resistance, 3rd gen TKI osimertinib was designed 
to specifically target and bind irreversibly to EGFR mutants [31, 32]. T790M+ patients with 
acquired resistance to 1st or 2nd gen TKIs will benefit from this drug for about another year 
before they become resistant again. The resistant mechanisms for osimertinib in 2nd line therapy 
have been gradually elucidated in the past several years [33, 34]. The general types of resistant 
mechanisms are very similar to what has been observed in patients treated with 1st and 2nd gen 
TKIs, although the distribution of specific mechanisms is different between the two scenarios 
(Figure 1.3C). On-target resistance conferring mutations were also identified in patients 
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receiving osimertinib: C797 and L718 were the most frequently mutated amino acid residues in 
osimertinib resistant tumors. C797S/G replaces the residue that osimertinib covalently binds to, 
thus dramatically reducing the efficiency of kinase inhibition [26, 27] whereas L718V/Q leads to 




Osimertinib has also been approved to be used in first-line therapy [19, 35]. Patients 
receiving first-line osimertinib show longer progression free survival, compared to 1st or 2nd gen 
TKIs (Figure 1.3A). However, they still inevitably develop acquired resistance. The resistant 
mechanisms for osimertinib in first-line setting have just started to be investigated. An early 
report on mechanisms of first-line osimertinib resistance in phase III FLAURA study suggest that 
MET amplification and EGFR C797S mutation are most frequently seen in patients with 
progressive disease as revealed by next-gen sequencing of circulating plasma DNA, although 
what causes acquired resistance in the majority of patients (about 70%) remain unknown [36]. 
Figure 1.3 EGFR TKI therapies approved for mutant EGFR lung cancer and mechanisms of acquired 
resistance to EGFR TKIs. (A) Summary of clinical use of EGFR TKIs in EGFR mutant lung cancer. (B-C) 
Mechanisms of acquired resistance to (B) 1st/2nd gen TKIs [30] and (C) 2nd line osimertinib [33,34]. 
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More extensive research in clinical specimens as well as pre-clinical models is required to 
elucidate the complex spectrum of resistant mechanisms and develop strategies to overcome 
drug resistance. 
 
Tolerance to EGFR TKIs in Mutant EGFR Lung Adenocarcinoma 
Incomplete Response to EGFR TKIs 
Lung adenocarcinomas driven by EGFR activating mutations become dependent on the 
constitutive activity of EGFR and therefore patients harboring these mutations show greater 
responses to EGFR tyrosine kinase inhibitors (TKIs) [37-39]. Three generations of EGFR TKIs 
have been developed so far and five targeted small molecule reagents have been approved to 
treat mutant EGFR lung cancer as first-line therapy. Third-gen TKI osimertinib, in particular, was 
designed to overcome secondary drug resistant mutation T790M and specifically target mutant 
EGFR, which spares wildtype EGFR and thus reduce potential side effects [31]. 
Despite the higher response rates and improved progression-free survival compared to 
traditional chemotherapy, EGFR TKIs are still not able to cause complete tumor regression in 
most cases, leaving a significant amount of tumor tissues even at the time point of maximal 
response (Figure 1.4) [19]. These drug tolerant residual tumor cells that survive TKI treatment 
serve as reservoir for relapse tumors, which is inevitable in patients receiving TKI therapies and 
is the major reason for treatment failure. In this regard, understanding the biology of drug 
tolerance may lead to identification of potential strategies to combat incomplete response and 
delay acquired resistance. 
 
Figure 1.4 Incomplete response to EGFR TKIs. Scan courtesy of Anne Chiang, MD, PhD 
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Current Knowledge about Drug Tolerance in Mutant EGFR Lung Cancer 
There has been extensive research on the persistent cancer cells in pre-clinical models of 
multiple types of cancer and various mechanisms of drug tolerance have been identified so far 
[40, 41]. 
Mutant EGFR lung cancer, in particular, has gained great research interest since drug 
tolerance to EGFR targeted therapy is prevalent in patients and always leads to acquired drug 
resistance. Studies of drug-tolerant persisters (DTPs) in established human EGFR mutant lung 
cancer cell lines have uncovered several pathways that contribute to drug tolerance including 
the NF-kB pathway and activation of NOTCH3 signaling through the non-canonical Wnt 
pathway [42, 43]. Additionally, the epigenetic regulator KDM5A was found to lead to a drug 
tolerant state that can be reversed upon TKI withdrawal [44] and upregulation of the anti-
apoptotic factor BCL2 was shown to promote survival leading to TKI-tolerant residual cells [45]. 
More recent findings suggest that activation of Aurora kinase A was able to promote cell survival 
through mitigation of apoptotic program induced by EGFR TKIs [46]. Studies of the chromatin 
structures in DTPs revealed a heterochromatin state mediated by repressive epigenetic 
modifications, which facilitated cell survival through suppression of stress-induced LINE-1 
expression [47]. 
Despite these findings mostly from in vitro studies, knowledge of which pathways are 
responsible for drug tolerance in vivo in patients are still limited. Indeed, studying residual 
disease has been particularly challenging in lung cancer, largely due to the difficulty of acquiring 
patient specimens at the time of maximal response. A recent study on single-cell analysis of 
TKI-treated patient specimen suggest that residual tumor cells exhibited an increased 
expression of healthy lung alveolar gene signature, shedding light on a potential transition 
between cell states upon development of drug tolerance [48]. In order to gain deeper insights 
into the mechanisms of drug tolerance in EGFR mutant lung cancer using patient specimens, 
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we leveraged patient-derived models to investigate the cellular and molecular properties of the 
cancer cells that persist despite dramatic tumor regression induced by EGFR TKI treatment, 
and to identify potential mechanisms of drug tolerance. 
 
Pre-clinical Models of Mutant EGFR Lung Adenocarcinoma 
Cell Line 
Cell lines used in mutant EGFR lung cancer research are derived from patient tumors 
harboring EGFR activating mutations (Table 1.1) [49] and play important roles in studying 
biology and mechanisms of resistance to EGFR TKIs in vitro [50]. In my thesis research, I will 
mainly focus on three human cell lines: PC9 (delE746-A750), H1975 (L858R+T790M) and 
HCC827 (delE746-A750). All the three lines show sensitivity to third-gen EGFR TKI osimertinib. 
Cell Line EGFR mutations 
PC9 delE746-A750 







Similar to human cell lines, patient-derived xenografts (PDXs) also originate from patient 
specimens but are transplanted into immune-deficient mouse to have the tumor cells grow in 
vivo. PDX models preserve many biological features of the primary patient samples, including 
histology, drug sensitivity and diversity and heterogeneity of patient tumors [51, 52]. Such 
models provide an opportunity to directly study patient tumor cells in vivo. Through co-analysis 
of patient specimens and PDXs, we are able to obtain more clinically relevant information that 
Table 1.1 List of selected human mutant EGFR lung cancer cell lines 
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eventually improves the understanding of the biology of mutant EGFR lung cancer and 
treatment outcomes. 
Despite the lack of a fully functional immune system in the murine host of PDX models, they 
are largely used to investigate tumor cell intrinsic mechanisms of drug tolerance and resistance. 
 
Genetically-Engineered Mouse Model 
In genetically-engineered mouse model of mutant EGFR lung cancer, human mutant EGFR 
is transduced into mouse genome and its expression is induced specifically in mouse lung 
epithelial cells to transform them into adenocarcinoma cells [53]. The mutant EGFR-driven 
mouse lung tumors retain the same TKI sensitivity as in human lung cancer patients. As the 
tumors are developed in immune-competent mice, transgenic mouse models allow for studies 
on cancer biology and drug tolerant mechanisms in the context of fully functional tumor 
microenvironment. In addition, mutant EGFR can be crossed with other transgenic alleles to 
investigate the roles of certain genes in tumor progression and drug resistance or add some 
features to the tumor cells (for example, lineage tracing by fluorescent marker). 
In my thesis research, I will use a modified GEMM of mutant EGFR lung cancer as well as 
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EGFR activating mutations are present in about 10-15% of lung adenocarcinomas and 
confer sensitivity to EGFR tyrosine kinase inhibitors. As a result of their efficacy in this patient 
population, EGFR TKIs are the first-line targeted therapy for LUAD patients with EGFR mutation 
positive tumors. Despite remarkable response rates to TKIs, tumor regression is not complete in 
most patients treated with EGFR TKIs and tumor cells persist despite treatment. Most prior 
studies have focused on understanding in vitro mechanisms of drug tolerance in human cell 
lines and the nature of the incomplete responses in patient specimens is still not fully 
understood. In order to learn more about the biology of residual cells in clinically relevant 
conditions, we leveraged patient-derived models to study drug tolerant residual disease. This 
chapter focuses on characterizing the PDX models and determining their capability to mirror 
incomplete response in patients, as well as gaining insights into the cellular and molecular 
properties of the PDX-derived drug-tolerant persisters. In a subset of PDXs that we tested, we 
observed a significant number of human mutant EGFR lung adenocarcinoma cells that survived 
osimertinib treatment. Subsequent cellular profiling of residual tumor cells indicated that, in 
these specific PDXs, they entered a quiescent state with cell cycle arrest and a low level of 
apoptosis. Through next-generation sequencing, we did not identify alterations in the mutational 
landscape of residual tumors compared to untreated tumors that could account for their 
persistence. However, we observed a dramatic change in the transcriptional profile between the 




Mutations in the Epidermal Growth Factor Receptor (EGFR) gene are found in ~15% of lung 
adenocarcinomas in the US and at higher frequencies in East Asian populations [4]. Tumors 
harboring these mutations exhibit sensitivity to EGFR tyrosine kinase inhibitors (TKIs) [37-39] 
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and five TKIs (erlotinib, gefitinib, afatinib, dacomitinib and osimertinib) are approved for the first-
line treatment of this disease. However, even with all of these agents and despite response 
rates of ~70-80%, tumors never regress completely and residual tumor remains [19, 20, 32]. 
These drug tolerant residual tumor cells then serve as reservoir for the subsequent emergence 
of acquired resistance, which inevitably develops in patients receiving EGFR TKI therapy, even 
with the TKI that has shown the greatest progression-free survival, osimertinib [26, 27, 33, 34]. 
Thus, it is critical for us to understand the mechanisms that underlie drug tolerance to develop 
strategies to limit the amount of residual disease and delay tumor relapse.  
Studies of drug-tolerant persisters (DTPs) have been mostly focused on established human 
EGFR mutant lung cancer cell lines so far. Discoveries in vitro have uncovered various 
mechanisms of drug tolerance, including signaling pathways promoting cell survival such as the 
NF-kB pathway and NOTCH3 pathway [42, 43], repressive chromatin state through epigenetic 
regulation [47], upregulation of the anti-apoptotic factor BCL2 [45], activation of cell cycle-
promoting factor Aurora kinase A [46] and metabolic shifts to fatty acid oxidation and enrichment 
of antioxidant program in cycling persisters [54]. However, mechanistic studies on TKI tolerance 
in vivo, especially in a clinically relevant setting, have just started to emerge. A recent study on 
single-cell analysis of EGFR TKI-treated patient specimens emphasized the role of both tumor 
cell intrinsic and microenvironmental programs in drug tolerant residual disease [48]. Despite 
the insights into drug tolerant mechanisms in human tumors, such study still has its limitation in 
that it is challenging to acquire sufficient patient specimens at the time of maximal response and 
the tumor cell abundance can vary between different specimens, which makes it difficult to 
analyze and interpret the data. One solution to addressing these challenges is to grow patient 
specimens as patient-derived xenografts (PDXs) in experimental animals like immunodeficient 
mice. PDX models are likely to preserve the biological features of patient tumors, especially 
tumor cell-intrinsic properties. The histological and pharmacological similarity between PDX and 
corresponding patient specimen makes it a good model to identify residual disease and 
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investigate drug tolerance in vivo. In this chapter, we characterized several mutant EGFR lung 
cancer PDXs to determine whether they can be used to study drug tolerance and leveraged 
these models to profile the cellular and molecular properties of the persistent cells and to 
identify potential mechanisms of drug tolerance. 
 
RESULTS 
Identification of drug-tolerant residual disease in PDXs of EGFR-driven lung cancer 
treated with the EGFR TKI osimertinib. 
To determine whether we could observe and isolate residual disease grown in vivo, we 
studied three EGFR mutant lung adenocarcinoma Patient-Derived Xenografts (PDXs). All of the 
PDXs were grown from biopsies of tumors that had acquired resistance to first- or second-
generation TKIs and all harbored an in-frame EGFR exon 19 deletion mutation and a secondary 
T790M mutation in EGFR known to confer resistance to 1st and 2nd generation TKIs (Figure 
2.1A-B). Analysis of the TKI sensitivity of these PDXs revealed that they were all resistant to the 
first-gen TKI erlotinib (consistent with the clinical course in the patient) and sensitive to the third-
gen TKI osimertinib (Figure 2.1C-E and S2.1A-C). To determine whether residual cancer cells 
were present in these PDXs following osimertinib exposure, we treated tumor-bearing mice with 
osimertinib for 4-6 weeks and monitored tumor size on a weekly basis. We found that, although 
YLR074 and YLR102 exhibited significant responses to osimertinib with an 85% decrease in 
tumor volume by the end of week 6 on drug, the response was incomplete and residual tumor 
remained. In contrast, YLR135 exhibited a complete response to osimertinib since its tumor 
volume shrank by over 98.5% after 4 weeks of treatment. These results indicate that different 
PDXs can exhibit variability in the depth of their response to osimertinib similar to that observed 
in patients (Figure 2.1C-E). 
To determine whether residual cancer cells were present, we collected tissue that remained 
following treatment once the tumor volume had reached a stable plateau and the tumor was no 
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longer shrinking (after 6 weeks of osimertinib treatment for YLR074 and YLR102 and 4 weeks 
for YLR135). Histological analysis revealed that for all three of the PDXs residual lung 
adenocarcinoma cells were present although the abundance of these cells was lowest in 
YLR135 that had shown the greatest response to osimertinib (Figure 2.1F). In all cases, we 
observed an increase in the stromal compartment in the residual disease sample. We confirmed 
the presence of residual tumor cells following osimertinib treatment, by performing 
immunohistochemical (IHC) staining for Nkx2-1, a lung epithelial cell marker (Figure 2.1G). In 
addition, we also used an antibody that specifically recognizes the EGFR exon 19 DEL mutant 
[55] present in YLR074 and YLR102 to further positively identify residual tumor cells (Figure 
2.1H). These experiments revealed that PDXs can be used to model and identify drug-tolerant 
disease. Considering the abundance of residual cells in YLR074 and YLR102, we used these 
PDXs for subsequent studies. 
Given that activity of the EGFR pathway is critical for tumor cell proliferation and survival in 
EGFR-driven lung cancer [28, 56], we determined the levels of proliferation and apoptosis in the 
two PDXs using IHC staining for ki-67 and cleaved caspase-3, respectively. We observed a 
dramatic reduction in ki-67+ nuclei in both YLR074 and YLR102 shortly following osimertinib 
treatment, which remained at a low level in residual tumors (Figure 2.2A-B), indicating that cell 
cycle progression is inhibited in residual tumor cells. Cleaved caspase-3 staining was induced at 
the beginning of TKI treatment and then returned to low baseline levels in residual disease 
(Figure 2.2C-D), suggesting that apoptosis triggered by EGFR inhibition subsided in drug 
tolerant tumor cells. Additionally, Western blotting of lysates obtained from untreated and 
residual tumors from YLR074 and YLR102 PDXs revealed effective suppression of EGFR 
phosphorylation indicating that tumor cell persistence was not due to incomplete activity of 
osimertinib in these tumor cells (Figure 2.2E-F). 
To investigate whether the residual state was reversible, we withdrew osimertinib in 2 mice 
for each PDX line after 4 weeks (for YLR102) or 6 weeks (for YLR074) of osimertinib treatment 
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at the time when residual disease was present (Figure S2.2A). Following osimertinib 
withdrawal, the tumors grew out in the absence of osimertinib with a 3 to 10-fold increase in 
tumor volume after 2-3 weeks off drug (Figure S2.2A-C) and the relapsed tumors retained 
histological features characteristic of each PDX line (Figure S2.2D). Relapsed tumors continued 
to produce the EGFR DEL19 mutant as determined by IHC (Figure S2.2D).  
Together these results indicate that drug-tolerant residual tumor cells are characterized by 
reduced proliferation and low levels of apoptosis, consistent with previous studies in human lung 
cancer cell lines [44, 46, 57]. 
 
The clonal and mutational landscape of osimertinib-tolerant disease was similar to that 
of untreated tumors. 
To investigate the mechanisms that account for the presence of residual disease in the 
PDXs, we first examined whether resistance-conferring mutations were present in the residual 
tumor cells compared to the pre-treatment specimens. Resistance-conferring mutations may 
pre-exist at a low frequency in treatment-naïve tumors and become clonally dominant during the 
process of drug treatment. Supporting this possible scenario, in the context of mutant EGFR 
lung cancers treated with first-gen EGFR TKIs, in some cases, the T790M mutation has been 
observed in pre-treatment patient tumor specimens and parental cell lines [50, 58-60]. To 
determine whether potential resistance-conferring mutations could account for drug tolerance, 
we performed whole-exome sequencing (WES) on untreated and residual tumors and 
compared sequencing results between the two conditions for each PDX line. We identified 242 
non-synonymous mutations in YLR074 and 194 non-synonymous mutations in YLR102 through 
this analysis. All of the mutations were present in both untreated and residual tumor cells, 
without loss or gain of any mutation following 6 weeks of osimertinib treatment.  
We also compared the variant allele frequencies (VAF) for the mutations in untreated and 
residual disease samples and found that these were largely unchanged after osimertinib 
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treatment (Figure 2.3A-B) suggesting the absence of selection of specific mutations by drug 
treatment. Consistent with this, pyrosequencing to confirm the allele frequency of the two 
disease-related EGFR mutations (the exon19 deletion and T790M mutations) revealed that the 
abundance of the EGFR mutations remained constant between untreated and residual disease 
and that the VAFs were comparable with WES (Figure 2.3A-C). To add statistical power to our 
observations, we performed a Fisher’s Exact Test to compare the VAF for every non-
synonymous mutation we identified in the two PDXs through WES. The majority of the 
mutations were not statistically significantly different (Figure S2.3) and for the small number of 
mutations that passed the test (7 in YLR074 and 11 in YLR102), we went on to determine 
whether these mutations affected the clonal architecture using the clonal analysis program 
PyClone [61]. As predicted by this program, the mutations were classified into different clusters 
based on the relative abundance of the mutations in the whole cell population and the cellular 
prevalence of each cluster did not change after osimertinib treatment in either of the PDXs, 
which suggests that development of drug tolerance did not alter the clonal architecture of the 
mutations in these mutant EGFR lung cancer PDXs (Figure 2.3D-E). The results of PyClone, 
together with the VAF analysis for the mutations identified in pre- and post-treatment PDXs, 
indicate that there is no specific genetic alteration being selected for or against during 
osimertinib treatment and the mutational landscape remains very similar between untreated 
tumor and residual disease. 
 
Persistent tumor cells exhibited dramatic changes in transcriptional profiles compared to 
untreated tumor cells. 
Having excluded genetic alterations as major contributors to the drug tolerant phenotype in 
our samples, we then turned to determine whether transcriptomic changes were present 
between the untreated and residual tumor using bulk RNA-sequencing. Alignment results 
showed that the majority of the sequencing reads were uniquely mapped to the human genome, 
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for all of the samples submitted for RNA-sequencing, indicating that samples were mostly 
composed of human tumor cells (Figure S2.4). Principal component analysis (PCA) of the data 
showed a clear demarcation between the PDXs from each patient, irrespective of treatment, 
indicating that features of the individual tumors dominate the transcriptional profiles. These data 
also revealed that YLR102 residual disease was transcriptionally very different from YLR102 
untreated tumor while YLR074 untreated and residual disease had more similar transcriptional 
profiles (Figure 2.3F).  
To identify pathways that were altered in the drug-tolerant disease in the PDXs, we 
performed pathway analysis using MetaCore and found deregulation of genes in development-
associated pathways including Wnt- and Hedgehog-signaling pathways in both PDXs (Figure 
S2.5A), which are able to promote survival of tumor cells during drug treatment [62-65]. The 
WNT pathway, specifically, has been shown to be enriched in residual disease specimens from 
patients with EGFR mutant lung cancer after TKI therapy and this is likely related to the 
activation of cell renewal and injury repair program [48]. A Hypoxia-Inducible Factor-1alpha 
(HIF1α) regulated transcriptional program was the top downregulated pathway in both PDXs 
following osimertinib treatment, which is probably a consequence of tumor shrinkage and 
reduced hypoxia in tumor microenvironment due to increased access to oxygen (Figure S2.5A). 
This is in line with the low-oxygen environment identified within PDX tumors, especially when 
they reach a relatively big size [66, 67]. Consistent with the decreased Ki-67 staining in residual 
disease, another prominent feature with residual PDX tumors is negative enrichment of cell 
cycle pathways, indicating suppression of cell cycle progression and supporting the hypothesis 
that tumor cells can survive treatment-induced pressure by exiting the cell cycle and entering a 
dormant state [68] (Figure S2.5A-B).  
Recent gene expression profiling of TKI-treated mutant EGFR lung cancer patient 
specimens revealed upregulation of a gene expression signature representative of normal 
alveolar cells [48]. In light of these findings, we examined the levels of expression of markers for 
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different lung epithelial cell types in our RNA-seq datasets [69]. Although the alveolar gene 
signature did not show significant enrichment in residual tumor cells in either of our PDX models 
(Figure S2.5C), the expression of specific genes in the list exhibited a constant increase in 
persister cells from both PDXs, including lung epithelial lineage factor Nkx2-1 and Aquaporin-4 
(Table 2.1). Furthermore, both PDXs are characterized with upregulation of club cell marker 
SCGB3A2 and downregulation of goblet and mucous cell marker MUC5B (Figure S2.5D). The 
results of gene expression profiling for untreated and residual PDX tumors suggest that drug 
tolerant residual disease represent a transcriptional state that differ from pre-treatment tumors 






Figure 2.1 PDXs of mutant EGFR lung cancer showed incomplete responses to osimertinib 
treatment. (A) Experimental design. (B) Basic information of the PDXs used in this study. (C-E) Tumor 
growth curves showing normalized tumor size of each mouse bearing (C) YLR074, (D) YLR102 or (E) 
YLR135 PDX following osimertinib treatment. Three biological replicates were included for each PDX 
line. (F-H) Histological features of the PDXs before and after treatment, as indicated by (F) H&E 
staining and IHC staining for (G) Nkx2-1 and (H) EGFR del19 mutant. Scale bar: 100μm. 
23 
   
Figure 2.2 Drug tolerant residual tumors exhibited low level of proliferation and apoptosis. (A-
B) IHC staining for Ki-67 in untreated, short-term (3 days) treated and residual (6 weeks) tumors of 
YLR074 and YLR102. Quantification of Ki-67 staining is shown in (B). Scale bar: 100μm. (C-D) IHC 
staining for cleaved caspase-3 in untreated, short-term treated and residual tumors of YLR074 and 
YLR102. Quantification of cleaved caspase-3 staining is shown in (D). Scale bar: 50μm. Significance 
for IHC staining was determined by unpaired t-test between untreated and residual groups. Each 
group contains six different fields of view. n.s.: p>0.05; ****: p<0.0001. (E-F) Immunoblotting for 
phospho-EGFR and total EGFR in untreated and residual tumors in (E) YLR074 and (F) YLR102. 




Figure 2.3 Drug tolerant residual disease 
showed minimal changes in mutational 
landscape but dramatic changes in gene 
expression profile compared to untreated 
tumors. (A-B) Dot plots comparing variant allele 
frequency of non-synonymous mutations 
identified by WES between untreated and 
residual tumors in (A) YLR074 and (B) YLR102. 
Each dot represents one non-synonymous 
mutation and disease-related EGFR mutations 
are highlighted in black. The blue dashed line 
running diagonally indicates where VAF of a 
certain mutation in residual disease is equal to 
that in untreated tumor. (C) Pyrosequencing for 
EGFR del19 and T790M mutations in untreated 
and residual tumors of YLR074 and YLR102. 
Significance was determined by multiple t-test. 
n=2 biological replicates for untreated group and 
n=3 biological replicates for residual group. n.s.: 
p>0.05. (D-E) Changes in clonality of mutations 
identified in (D) YLR074 and (E) YLR102 after 
osimertinib treatment, as predicted by PyClone 
program. The mutations were separated into 
multiple clusters and the number of mutations in 
each cluster is indicated within the brackets. (F) 
PCA plot visualizing the difference in gene 
expression profiles between untreated and 
residual tumors for YLR074 and YLR102. 
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DISCUSSION 
Incomplete response to drug treatment is almost inevitable in human cancer. For every 
therapy given to patients, whether it is radiotherapy, traditional chemotherapy or targeted 
therapy, tumor cells cannot be fully eradicated in most of the cases. During the clinical course, 
the tumor burden usually stays stable in the presence of treatment, followed by progression in 
either primary or metastatic sites upon acquired resistance. The biology of drug tolerant residual 
disease in mutant EGFR-driven lung cancer has mainly been learned from in vitro research on 
human cell lines and more recently from primary patient biopsies [40, 41, 48]. Appropriate 
models are required to gain deeper insights into the mechanisms of drug tolerance in human 
tumors. Patient specimens, depending on the sampling approach, are usually limited and 
contain only a small number of tumor cells. Expanding tumor cells in a robust system is thus 
critical to obtain sufficient materials for multitudinal profiling. We chose to grow patient tumor 
tissues as PDXs in immunodeficient mice given that this model can retain both biological and 
clinical traits of the original human samples [51, 52]. Indeed, PDX mouse models have been 
used to model drug tolerance and acquired resistance in melanoma and successfully mimic the 
treatment outcomes of targeted therapy in patients [70]. In the PDXs that we interrogated in this 
thesis research, they exhibited a histology of aggressive adenocarcinoma, harbored the driver 
mutations and maintained the TKI sensitivity, which are all characteristic of the patient tumors 
that they were derived from. Two out of the three models also showed incomplete responses to 
third-gen TKI osimertinib, providing opportunity to study drug tolerant residual disease in a more 
clinically-relevant setting. 
Despite the similarity between PDXs and human tumors, as an in vivo model, PDXs are not 
perfect for detailed mechanistic studies such as genetic manipulation, CRISPR screening and 
subsequent functional experiments. To address the questions related to molecular mechanisms, 
ongoing work is focused on growing cancer cells as 2D or 3D cultures that can be genetically-
modified and assayed more easily. 
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Cellular profiling of persistent tumor cells revealed that most of them entered a quiescent G0 
stage as manifested by Ki-67 negativity and low level of apoptosis, which is consistent with cell 
cycle-arrested DTPs identified in human cell lines [44]. The non-proliferative cell state is able to 
protect malignant cells from cancer treatments, which preferentially target the fast-dividing cell 
population. This quiescent state shares a great extent of similarity in biological features with 
dormant tumor cells and in both scenarios cells are insensitive and refractory to treatment [68]. 
However, detailed molecular profiling suggests that DTP is likely a heterogeneous cell 
population. Recent single-cell analysis of persister cells from human EGFR mutant lung cancer 
cell lines revealed a DTP subpopulation that was not cell cycle arrested, which may contribute 
to the eventual tumor cell regrowth [54]. In line with the in vitro study, most up-to-date study on 
a new PDX sample in our cohort (data not shown) suggests that residual disease consisted of a 
large number of Ki-67+ cells, indicating the possibility that depending on the tumor intrinsic 
features drug tolerant cells can be cell cycle-active rather than quiescent.  
Secondary drug resistant mutations in EGFR are major contributors to the mechanisms of 
acquired resistance to all the EGFR TKIs that have been approved so far. These resistant cells 
can arise either de novo or through selection of pre-existing mutation-positive subpopulation 
[50]. In order to understand the mutational landscape of residual tumor cells, which are prelude 
to relapse tumors, we performed WES to identify any resistance-conferring mutations that were 
enriched in osimertinib-tolerant cells compared to untreated tumors. We did not observe on-
target EGFR mutations such as C797S and L718V/Q that are known to cause osimertinib 
resistance in either untreated or residual tumor cells [23, 26, 27], nor any activating mutations in 
KRAS that can bypass EGFR pathway [5, 23]. Furthermore, the allelic frequency and clonal 
architecture of all the non-synonymous mutations identified through WES remained quite similar 
between untreated cells and DTPs in the PDX models. The analyses of mutational status in the 
PDXs before and after treatment suggest that pre-existing drug resistant mutations may not 
contribute to the TKI tolerance in the PDX cohort that we examined. This is consistent with other 
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studies indicating that the transcriptional landscape is the major difference between untreated 
and residual disease. 
Inter-tumoral heterogeneity is common in cancer patients. Tumors that are categorized in 
the same histological subtypes and harbor the same oncogenic driver mutations may still exhibit 
great extent of transcriptional difference due to genetic and epigenetic distinctions. The two 
PDXs profiled in this chapter showed clear difference in gene expression when not treated with 
TKI and osimertinib induced transcriptomic changes to different extent in different PDXs, as 
revealed by RNA-seq. How this transcriptional discrepancy between patients determines 
responses and tolerance to EGFR-targeted therapy is still not well understood. As discussed in 
the next chapter, this transcriptional heterogeneity is not limited to PDXs and can be extended 
to human lung cancer cell lines derived from different patients and the cellular contexts can 
affect the role of certain genes in driving TKI tolerance. To investigate drug tolerant mechanisms 
more comprehensively and understand the heterogeneity between patients, ongoing work is 
focused on characterizing additional patient-derived models and synthesizing information 
obtained from different sources. 
 
EXPERIMENTAL PROCEDURES 
Establishing PDXs in immune-deficient mice. 
Immune-deficient NSG mice were purchased from The Jackson Laboratory. Mouse handling 
and in vivo experiments were performed following the protocol approved by Institutional Animal 
Care and Use Committee at Yale University. 
Fresh or fresh-frozen tumor tissues were processed with tumor dissociation kit (Miltenyi 
Biotech, 130-095-929) to generate single cell suspension. Cells were spun down and 
resuspended in Matrigel (Corning, 356237), followed by subcutaneous injection into the flanks 
of NSG mice. Materials equal to 100mm3 tumor tissues were injected into each mouse. Tumors 
were let to grow freely until they reached desirable volume for further studies. 
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Drug treatment in vivo. 
Tumor-bearing mice were treated with osimertinib at 25mg/kg for five consecutive days each 
week when their tumor size reached around 300mm3. The treatment lasted for 6 weeks before 
drug tolerant residual tumor was excised, unless stated otherwise. Tumor burden was 
measured by caliper once or twice per week. 
Osimertinib (kindly provided by AstraZeneca) was dissolved in 0.5% methylcellulose 
(Sigma-Aldrich, M0512) at 5mg/ml, with overnight stirring. 
 
Immunohistochemistry staining. 
Tumor tissues were fixed in 4% paraformaldehyde (Electron Microscopy Services, 15714-S) 
and embedded in paraffin. FFPE tissue sections were deparaffinized in Clear-Rite 3 (Thermo 
Scientific, 6901) and then rehydrated in serially diluted ethanol before heat-induced epitope 
retrieval in antigen unmasking solution (Vector Laboratories, H-3300). The tissue sections were 
then treated with 3% hydrogen peroxide (J.T.Baker, 2186-01) to remove endogenous reactive 
oxygen species and blocked with goat serum (provided by VECTASTAIN Elite ABC-HRP kit, 
PK-6101), followed by incubation with primary antibody at 4 degree overnight. The sections 
were treated following the protocol in VECTASTAIN kit, stained with NovaRED substrate kit 
(Vector Laboratories, SK-4800) and counterstained with hematoxylin (Vector Laboratories, H-
3401). Finally, sections were dehydrated and mounted in Permount (Fisher Scientific, SP15-
100). 





Tissue powder or cells were lysed in RIPA buffer to extract proteins [39]. The protein 
concentration was quantified using DC protein assay (Bio-Rad, 5000116), followed by protein 
denaturation in 4X sample buffer (Bio-Rad, 1610747) supplied with 40mM DTT (Sigma-Aldrich, 
D9779). Proteins of equal amount for each sample were loaded onto a 4-20% SDS-PAGE gel 
(Bio-Rad, 4568093) and electrophoresis was performed at constant voltage until protein ladder 
(Bio-Rad, 1610375) was well-separated. Proteins were then transferred to nitrocellulose 
membrane (Bio-Rad, 1620112) and blocked in 5% non-fat dry milk (AmericanBio, AB10109-
01000). Blots were incubated with primary antibody at 4 degree overnight with constant shaking. 
The membranes were then washed in TBS (Bio-Rad, 1706435) with 0.1% Tween-20 (Sigma-
Aldrich, P7949), incubated with secondary antibody (CST, 7074, 1:2000) at room temperature 
for 1 hour and washed again in TBST. The blots were developed using SuperSignal West Pico 
(Thermo Scientific, 34580) or Femto (Thermo Scientific, 34096) chemiluminescent substrate 
and chemiluminescence was detected in ChemiDoc MP gel imaging system (Bio-Rad). 
Primary antibodies used for western blotting: pEGFR (CST, 3777), EGFR (CST, 4267), 
EGFRdel19 (CST, 2085), Actin (Santa Cruz, sc47778 HRP, 1:2000). All the primary antibodies 
were diluted in 5% non-fat dry milk by 1:1000, unless stated otherwise. 
 
Whole exome sequencing.  
PDX tumors were harvested and flash-frozen in liquid nitrogen. Frozen tissues were ground 
into powder with mortar and pestle on top of dry ice. Genomic DNA was extracted from tissue 
powder using AllPrep DNA/RNA mini kit (Qiagen, 80204). Genomic DNA quality is determined 
by estimating the A260/A280 and A260/A230 ratios by nanodrop, both of which should be > 1.8, 
and by 1% agarose gel electrophoresis. High quality DNA will migrate as a single high 
molecular weight band. DNA samples were fragmented, ligated to adaptors and barcoded, 
followed by exome target capture with xGen Exome Panel (IDT). The libraries were sequenced 
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on illumina HiSeq4000 sequencer at Yale Center for Genome Analysis (YCGA) using 100bp 
pair-end sequencing to generate data with 200X coverage per sample. 
 
Bulk RNA-sequencing.  
RNA was extracted from tissue powder or cell lines using AllPrep DNA/RNA mini kit. RNA 
integrity was determined by running an Agilent Bioanalyzer gel, which measures the ratio of the 
ribosomal peaks. Samples with RIN values of 7 or greater proceeded to library prep. RNA-seq 
libraries were constructed using KAPA mRNA HyperPrep Kit (Kapa Biosystems, KR1352) and 
sequenced on illumina HiSeq2500 sequencer using 75bp single-end sequencing to generate 
around 30M reads per sample. 
 
WES data analysis. 
WES raw data were processed and analyzed with similar methods as described before [17]. 
In brief, Xenome [71] was used to classify the origin of sequencing reads and filter out the reads 
originated from mouse. The remaining sequencing reads were aligned to the reference genome 
(hg19) using BWA-MEM [72] followed by GATK Best Practices workflow [73]. Somatic 
mutations were identified using MuTect2 [74] and Pisces [75] and in-house scripts were used to 
filter out potential false positives. Likely damaging variants were annotated including premature 
termination, canonical splice site, frameshift insertion/deletion, and missense mutation using 
Annovar [76]. All somatic mutations were manually confirmed by visualizing read plots. 
 
Estimation of tumor clonal population structure. 
PyClone [61] was used to infer the subclonality in tumor samples. The software was 
implemented to cluster somatic mutations incorporating the variant allele frequencies obtained 
by MuTect2, using the hierarchical Bayes statistical model and the cellular prevalence of 
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somatic mutations is estimated from a Dirichlet Process. Clusters containing at least 2 
mutations and a mean of VAF greater than 5% were used. 
 
RNA-seq data analysis. 
RNA-seq raw data generated from PDXs were processed with BMX-seq pipeline as 
described before [77]. In brief, sequencing reads were trimmed of adaptor sequences using 
Trim Galore and mapped to a combined human (hg38) and mouse (mm10) genome using 
STAR [78] to separate the components of the two species and to a combined transcriptome 
(GENCODE v24 for human, vM10 for mouse) to add gene annotation. Then the uniquely 
mapped reads were counted per annotation using featureCounts [79]. Finally, the counting 
matrix went through DESeq2 package [80] to identify the genes that are differentially expressed 
between different conditions. 
 
Pathway enrichment analysis. 
DEG lists with log2FoldChange and p-value for individua genes were used as input for 
MetaCore software (https://portal.genego.com/). Enrichment analyses were performed only for 
genes with log2FC>1 or <-1 and p-value<0.05, unless stated otherwise. 
 
Gene Set Enrichment Analysis.  
Differentially expressed genes identified in bulk RNA-seq were sorted and ranked by their 
Wald statistic value as calculated by DESeq2 pipeline. Pre-ranked gene list was analyzed 
against proper gene signatures through the GSEA software 3.0 downloaded from GSEA 
website (https://www.gsea-msigdb.org/gsea/index.jsp) [81, 82]. Alveolar gene signature was 





  Figure S2.1 Mutant EGFR lung cancer PDXs were resistant to erlotinib. (A-C) Tumor growth 
curves showing normalized tumor size of each mouse bearing (A) YLR074, (B) YLR102 or (C) 
YLR135 PDX following erlotinib treatment. 
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  Figure S2.2 Tumor cells were still viable after development of drug tolerance. (A) Experimental 
schema of tumor relapse assay for YLR074 and YLR102. (B-C) Relapse tumor burden normalized to 
residual disease for (B) YLR074 and (C) YLR102 after 2 and 3 weeks off drug, respectively. (D) H&E 
staining and IHC staining for EGFR mutant on tissue sections from YLR074 and YLR102 relapse 
tumors. Scale bar: 100μm. 
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  Figure S2.3 The changes in VAF after osimertinib treatment remained statistically insignificant 
for the majority of the non-synonymous mutations identified by WES. (A-B) Dot plots depicting 
VAF of the mutations in the two PDX lines, similar to what is shown in Figure 2.3A-B. The dots 
highlighted in red represent the mutations that pass the Fisher’s Exact Test (p-value<0.05). 
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  Figure S2.4 Human tumor cells were major components of the PDX tumors. Bar plots showing 
the proportion of bulk RNA-seq reads mapped to human (hg) or mouse (mm) genome with or without 
assigned features for each single tumor sample of YLR074 or YLR102. 
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Figure S2.5 Transcriptional 
features of drug tolerant residual 
cells from PDX models. (A) Results 
of MetaCore pathway analysis 
showing the pathways predicted to be 
up- or down-regulated in residual 
disease in both PDXs. DEGs were 
filtered with threshold=1; p<0.05 (B) 
Enrichment plots for two cell cycle-
related gene signatures analyzed in 
residual vs untreated tumors. (C) 
Enrichment plots for lung alveolar 
gene signatures analyzed in residual 
vs untreated tumors. (D) Expression 
level of selected lung epithelial marker 
genes in untreated and residual tumor 




Log2FC p-adj Log2FC p-adj 
NKX2-1 0.43 0.039 0.44 5.55E-06 
AQP4 3.28 1.17E-33 6.08 6.47E-186 
 
  
Table S2.1 Changes in the expression of selected lung alveolar signature genes in osimertinib-
tolerant cells vs untreated cells from both PDXs.  
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Histological transformation and lineage transition are well-described mechanisms of 
acquired resistance to EGFR TKIs whereas detailed cellular and molecular profiling of drug 
tolerant persister cells that precede these changes in relapsed tumors remain poorly delineated. 
To gain deeper insights into the potential lineage plasticity and evolution of DTRCs, we further 
investigated the gene expression profiles of untreated and residual tumor cells in PDXs as 
discussed in last chapter. Through these analyses we found upregulation of the neuroendocrine 
lineage transcription factor ASCL1 in one of the PDX models following osimertinib treatment. 
ASCL1 expression was accompanied by an increase in the expression of its target genes in 
residual cells. Single-cell RNA-seq revealed that this ASCL1-mediated transcriptional program 
was enriched in a subpopulation of untreated tumor cells that shared similar transcriptomic 
features with DTRCs, suggesting that persister cells may arise from the selection of pre-existing 
TKI tolerant clones. Functional studies of ASCL1 in established human cell lines indicate that in 




LUAD tumors harboring EGFR activating mutations are more sensitive and thus benefit 
more from EGFR TKI therapy, however, acquired resistance inevitably occurs to all EGFR TKIs. 
Despite the relatively thorough investigation of on-target EGFR resistance conferring mutations 
and bypass pathway activation [21, 30], the biology and evolution process underlying another 
resistance mechanism, such as phenotypic transformations of the tumors, are not well 
understood. Mutant EGFR-driven lung adenocarcinoma cells that undergo either SCLC 
transformation or EMT become less dependent on EGFR activity and lose sensitivity to EGFR 
TKIs. Despite the active searching for therapeutic approaches to overcome or prevent these 
mechanisms of acquired resistance [49, 83], chemotherapy is still the most common therapeutic 
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option for patients. This lineage plasticity that can lead to phenotypic transformation is not 
limited in EGFR mutant lung cancer and has been identified in LUAD treated with other targeted 
therapies (e.g. ALK inhibitor) or immune checkpoint inhibitors and other types of cancer as well 
[84-87]. For example, in prostate cancer patients receiving anti-androgen therapy, 
adenocarcinoma cells can undergo neuroendocrine differentiation giving rise to an aggressive 
and drug-resistant cancer [87]. Besides trans-differentiation into neuroendocrine lineage, 
squamous cell carcinoma transformation has also been identified in lung cancer patients 
receiving first-line osimertinib [88]. This commonality across various clinical settings clearly 
indicates the existence of mechanisms to overcome the lineage barrier between 
adenocarcinoma and neuroendocrine cancer or squamous cell carcinoma under the selective 
pressure of targeted and other therapies. However, little is known about the determinants of 
lineage transition in that patient subset and how it develops in a stepwise manner. Drug tolerant 
residual disease, as an intermediate stage, is a critical step during the development of tumor 
relapse and the studies of its biology pave the way for understanding the lineage plasticity and 
heterogeneity of cancer cells and identification of potential therapeutic vulnerabilities.  
This chapter is focused on the context-dependent role of NE lineage factor ASCL1 in driving 
TKI tolerance and promoting an EMT signature in mutant EGFR lung cancer. ASCL1 encodes a 
basic helix-loop-helix transcription factor, which plays a central role in both physiological and 
pathological processes, including the development of lung neuroendocrine cells and initiating 
small cell lung cancer in both humans and genetically-engineered mouse models [89-92]. 
Approximately 8% of lung adenocarcinomas are also positive for ASCL1 and define a subset of 
these tumors with neuroendocrine features [93]. Using single-cell RNA-sequencing, we 
confirmed the presence of a population of persister-like cells that express ASCL1 signature 
genes at a high level even before TKI treatment. Moreover, we demonstrate functionally that 
ASCL1 led to drug tolerance in cells that were permissive to activation of an epithelial to 
mesenchymal gene expression program. All the results that we obtained from different model 
41 
systems suggest that ASCL1 may be a potential driver of tolerance to EGFR tyrosine kinase 
inhibitors in mutant EGFR lung cancer. 
 
RESULTS 
An ASCL1-mediated transcriptional program was present in drug tolerant residual 
disease. 
The dramatic difference in the transcriptional profiles of untreated tumor vs. residual disease 
in YLR102 (Figure 2.3F) raised the possibility that drug tolerance, in this case, could be due to 
a population of cells with a new TKI resistant identity altogether. Further examination of 
individual differentially expressed genes between residual disease and untreated tumor 
revealed a dramatic upregulation of ASCL1 in YLR102 (but not in YLR074) (Figure 3.1A). This 
was especially intriguing because ASCL1 is a neuroendocrine (NE) lineage transcription factor 
that is highly expressed in one of the molecular subtypes of SCLC [94]. Since SCLC 
transformation is one of the mechanisms of resistance to TKI therapies in mutant EGFR lung 
cancer [29], ASCL1 upregulation in response to osimertinib treatment could be associated with 
the neuroendocrine differentiation of these tumors. Moreover, ASCL1 has been shown to be a 
pioneer factor given its ability to reprogram fibroblasts to neuronal cells [95]. 
To further confirm these observations, we examined expression of several canonical ASCL1 
downstream targets including BCL2, DLL3, PROM1 and RET [92, 93]. All of these targets were 
among the top upregulated genes in YLR102 residual disease (Figure 3.1B-E), and the 
changes were retained at the protein level (Figure 3.1F). Indeed, while phosphorylation of 
EGFR was effectively suppressed in the residual tumor, ASCL1 and its downstream targets 
were all abundantly produced while they were undetectable by immunoblotting in the bulk 
untreated tumor. Gene set enrichment analysis (GSEA) revealed that two previously published 
ASCL1 gene signatures [92, 93] were positively enriched in YLR102 residual tumor cells 
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(Figure 3.1G). Together these data indicate the presence of an ASCL1-mediated transcriptional 
program in the residual disease from the YLR102 PDX.  
Next, given the role that ASCL1 plays in the establishment of a neuroendocrine program we 
investigated whether the YLR102 residual disease exhibited features of neuroendocrine 
differentiation. In this regard, YLR102 residual disease retained histological features of lung 
adenocarcinoma (Figure 2.1F) and did not show a dramatic increase in classical 
neuroendocrine markers such as Synaptophysin, Chromogranin A and INSM1 (Figure S3.1). 
Collectively, these data suggest that an ASCL1-mediated transcriptional program is 
enriched in TKI-tolerant residual disease of EGFR mutant lung cancer despite no evidence in 
neuroendocrine differentiation. 
 
Rare ASCL1-high tumor cells pre-existing in untreated tumors were selected for upon 
osimertinib treatment. 
Drug tolerant residual cells can emerge through the selection of a rare drug-tolerant 
population of cells present in the bulk tumor. Alternatively, treatment-induced changes in a 
subset of cancer cells could lead to drug tolerance. To determine the origin of the drug-tolerant 
ASCL1+ positive cells, we stained untreated and residual tumors for ASCL1. ASCL1 showed 
clear nuclear staining in YLR102 residual tumor samples, which was consistent with its role as a 
transcription factor (Figure 3.2A-B). ASCL1+ cells were present, but sparse, in untreated tumor 
samples, as evidenced by immunohistochemistry (Figure 3.2A-B). This led us to hypothesize 
that a small number of ASCL1hi tumor cells pre-existed in untreated tumors and got selected for 
by osimertinib treatment. To validate this hypothesis, we used single-cell RNA sequencing to 
determine whether we could identify a rare drug tolerant cell population in the untreated tumor. 
Live EpCAM+ cells were sorted from a dissociated tumor cell suspension to specifically 
enrich for human tumor cells (Figure S3.2A) since isolated EpCAM+ cells expressed mutant 
EGFR (Figure S3.2B) and the EPCAM gene is expressed in both untreated and residual 
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tumors, as shown by RNA-sequencing (Figure S3.2C). After processing of raw data, we 
identified 5663 untreated cells and 1168 residual cells that would be incorporated into the 
following analyses. Consistent with findings from our bulk RNA-seq data (Figure 2.3F), the 
clustering results show a clear separation between untreated and residual cells (Figure 3.2C-
D). We also identified a small group of untreated cells that clustered together with residual 
tumor cells in cluster 2 (Figure 3.2C-D and H), underscoring the transcriptional similarity 
between these two cell populations in this specific cluster, whereas the majority of untreated 
cells clustered separately from residual cells in the UMAP plot. 
Similar to bulk RNA-seq findings, ASCL1, BCL2 and RET were more highly expressed in 
drug tolerant residual cells (DTRCs) compared with untreated tumor cells (Figure 3.1A-E and 
3.2E-G). The subpopulation of untreated tumor cells that clustered with DTRCs also showed 
enrichment of ASCL1 and its target genes (Figure 3.2I) providing further evidence that ASCL1 
positive DTRC-like tumor cells pre-exist in the untreated tumors and are selected for during 
treatment with osimertinib. To examine whether selection of a pre-existing DTRC-like 
subpopulation was unique to the YLR102 PDX we also performed single cell analysis of 
untreated and residual cells from the YLR074 PDX and found that clusters 6 and 12 were 
composed of cells from both conditions, indicating that cells transcriptionally resembling DTRCs 
were also present in untreated YLR074 tumors, even though ASCL1 was not the driver of TKI 
tolerance in this PDX line (Figure S3.3). These data indicate the presence of a population of 
untreated tumor cells having properties of DTRCs which upon osimertinib treatment survive and 
become the main cell population present in residual tumors. 
 
ASCL1 triggered epithelial-to-mesenchymal transition (EMT) which was the likely 
mediator of drug tolerance. 
To investigate if and how ASCL1 causes drug tolerance, we turned to human mutant EGFR 
lung adenocarcinoma cell lines for mechanistic studies. We used doxycycline-inducible vectors 
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to express ASCL1 in HCC827, PC9 and H1975 cells and evaluated the impact of ASCL1 on 
colony formation and viability in the presence of osimertinib (Figure 3.3A and S3.4A-B). In 
HCC827 cells transfected with the empty vector (HCC827-EV), osimertinib eradicated colonies. 
In contrast, in ASCL1-transfected cells (HCC827-ASCL1), the colony size was reduced by 
osimertinib but a significantly higher number of colonies survived treatment (Figure 3.3B-C). 
Further, HCC827-ASCL1 cells also showed a decrease in osimertinib sensitivity compared to 
EV cells, as evidenced by a shift of the dose-response curve in a growth inhibition assay 
(Figure 3.3D). The differential behavior of HCC827-EV and -ASCL1 cells when treated with 
osimertinib indicate that ASCL1 promotes survival and drives drug tolerance in this cell line. In 
PC9 and H1975 cells, ectopic ASCL1 expression did not affect the clonogenic activity of the 
cells nor did it affect osimertinib sensitivity (Figure S3.4C-F). These data suggest that the ability 
of ASCL1 to cause tolerance to EGFR TKIs depends on the cellular context.  
To gain mechanistic insights into ASCL1-mediated TKI tolerance and determine what 
distinguishes cells that are permissive to the phenotypic changes driven by ASCL1 and those 
that are not, we performed RNA-seq on HCC827 and PC9 cell lines transfected with the EV or 
ASCL1 vectors in the absence of osimertinib (vehicle) or treated with osimertinib for 3 and 10 
days to acquire short-term treated cells and drug tolerant persisters, respectively. Gene 
expression profiling of the cell lines in different conditions indicated a more dramatic 
transcriptional change in the untreated HCC827 cell line compared to PC9 cells upon ASCL1 
overexpression as revealed through principal component analysis (Figure S3.5A). These 
findings were consistent with the observation that ASCL1-transfected HCC827 cells exhibited 
morphological changes including increased number of protrusion-like structures and growth in 
individual cells rather than in clusters, which were not seen in PC9 cells (Figure 3.4A). Pathway 
analyses performed on the RNA-seq data from the two cell lines using MetaCore indicated that 
EMT was the top upregulated pathway in HCC827 cells following ASCL1 expression but it was 
not enriched in PC9-ASCL1 cells (Table 3.1). Given the known association of EMT with TKI 
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resistance and activation of the EMT program upon ASCL1 expression in HCC827 cells, we 
decided to further investigate the relationship between ASCL1-mediated EMT and TKI 
tolerance. We examined the expression of individual epithelial and mesenchymal markers in our 
RNA-seq datasets. Although these markers did not change significantly in PC9-ASCL1 cells 
versus EV cells, their expression was altered dramatically in HCC827 cells following ectopic 
ASCL1 expression, with a significant downregulation of epithelial markers (E-cadherin and 
Epcam) and upregulation of mesenchymal markers (N-cadherin and Vimentin), indicative of 
EMT (Figure 3.4B and S3.5B). This notion was further supported by GSEA, which showed 
positive enrichment of an EMT gene signature in HCC827-ASCL1 cells as compared to EV 
cells, but not in PC9 cells (Figure 3.4C).  
The EMT phenotype identified in ASCL1-transfected HCC827 cells was strengthened by TKI 
treatment. As drug tolerance developed, HCC827-ASCL1 cells exhibited greater enrichment of 
EMT features compared to untreated cells (Figure 3.4B-C and Table 3.1). In contrast to the 
EMT-mediated drug tolerance in ASCL1-overexpressed cells, EV-transfected HCC827 cells did 
not persist upon osimertinib treatment and lacked robust enrichment of EMT features (Figure 
3.3B and 3.4B). Inspection for the upstream EMT-related transcription factors revealed that 
ZEB family members shared a similar transcriptional pattern with mesenchymal lineage markers 
after ASCL1 overexpression and osimertinib treatment, and such a pattern was largely missing 
for SNAI and TWIST family members (Figure 3.4B and S3.5C). This suggests that the ASCL1-
induced EMT phenotype in HCC827 cell line may be mediated by ZEB family members.  
We also checked the bulk RNA-seq datasets of the PDX samples for several EMT markers. 
Consistent with the discoveries from cell lines, in YLR102 residual disease where we identified 
ASCL1 upregulation, E-cadherin was downregulated and Vimentin was upregulated as drug 
tolerance developed and such changes were not observed in the ASCL1-unrelated case 
YLR074 (Figure S3.5D). 
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Taken together, the results obtained both in vitro and in vivo suggest that ASCL1 is able to 
drive tolerance to EGFR TKI in mutant EGFR lung cancer by triggering EMT program. 
 
ASCL1 was expressed and drove neuroendocrine phenotype in a subset of TKI-resistant 
EGFR mutant lung cancer with SCLC transformation. 
ASCL1 has been implicated as a dominant molecular identifier and master regulator of NE 
differentiation in a subgroup of primary SCLC [94] but little is known about the molecular 
subtyping of mutant EGFR lung adenocarcinoma that transforms to SCLC upon TKI exposure. 
In order to gain insights into the drug resistance mechanisms in a clinically-relevant setting, we 
developed repeat biopsy program at Yale Cancer Center that allowed us to collect treatment-
naïve and TKI resistant tumor specimens from the same patients and use these samples for a 
variety of applications including histological analysis, NGS, growing them as PDXs and cell lines 
etc. We chose to analyze the specimens that showed SCLC transformation as mechanism of 
acquired resistance to EGFR TKIs in our patient collection and characterized their genetics and 
expression of neuroendocrine marker genes. Since RB1 and TP53 loss are the most common 
genetic alterations identified in SCLC [96], we first examined the mutational status and copy 
number changes of these two genes in the patient specimens where genetic profiling data are 
available. Consistent with SCLC, both RB1 and TP53 were frequently mutated in SCLC 
transformed EGFR mutant lung cancer as well (3 out of 4) (Figure 3.5A). Copy number variants 
for the two genes were not commonly identified in most of the patient samples except for 
YUL0125, which showed a copy number gain of RB1 (Figure 3.5B). YUL0125 harbors a 
frameshift deletion in RB1 so the amplified gene copies are likely to still carry this deleterious 
mutation given the role of RB1 as a tumor suppressor gene. Further detection of RB1 proteins in 
tumor cells by IHC staining is required to validate the functional consequences of the genetic 
alterations. 
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As revealed by recent studies, SCLC can be divided into multiple molecular subgroups 
based on the expression of signature transcriptional regulators including ASCL1, NEUROD1 
POU2F3 and YAP1 [94]. We performed histological analyses on patient tumor samples that 
underwent SCLC transformation (Figure 3.5C) and examined the expression pattern of three 
molecular identifiers of SCLC (ASCL1, NEUROD1 and YAP1). Three out of five tumors 
(YLR051, YUL0025 and YUL0125) exhibited positive staining for ASCL1 and one tumor 
specimen (YLR035) showed weak positivity for NEUROD1 (Figure 3.5D-E). YAP1 only showed 
focal staining in YLR051 and YLR035 and is thus unlikely to be the transcriptional regulator that 
defines these cases (Figure 3.5F). YUL0003 is negative for all the three markers and the 
regulator of NE program in this particular case requires further investigation. The heterogeneous 
expression of these transcriptional regulators in SCLC transformed EGFR mutant lung cancer is 
consistent with what is identified in SCLC in general, highlighting that the transcriptional 
heterogeneity of SCLC is recapitulated in EGFR mutant tumors that transform to SCLC upon 
TKI treatment. 
ASCL1 is able to drive neuroendocrine differentiation and required for maintaining NE status 
in NE-high SCLC [91, 92, 97, 98]. To characterize the NE features in ASCL1-positive SCLC 
transformation cases, we examined the expression level of multiple NE markers in pre-
treatment and resistant YUL0025 tumor samples through bulk RNA-seq. We observed a 
dramatic upregulation of ASCL1 and NE marker genes as the tumor cells acquired resistance to 
EGFR TKI and transformed into SCLC (Table 3.2), indicating a neuroendocrine phenotype in 
resistant tumor cells. The cellular and molecular profiling of the SCLC transformation cases 
suggest that expression of SCLC molecular identifiers is heterogeneous, with a subgroup being 
positive for ASCL1, which is correlated with a strong NE signature. The expression of 
neuroendocrine lineage factor ASCL1 in TKI-tolerant residual disease might pave the way for 





Figure 3.1 An ASCL1 gene expression program was specifically activated in YLR102 residual 
tumor cells. (A-E) Expression level of ASCL1 and some of its target genes in untreated and residual 
tumors of YLR102, as evidenced by bulk RNA-seq. Significance for gene expression changes was 
determined by unpaired t-test between untreated and residual groups. n=2 biological replicates for 
untreated group and n=3 biological replicates for residual group. n.s.: p>0.05; **: p<0.01; ***: p<0.001; 
****: p<0.0001. (F) Immunoblotting to detect protein level of ASCL1 and its downstream targets. Each 
lane represents protein lysates from an individual tumor. (G) GSEA results showing enrichment of two 







Figure 3.2 ASCL1hi persister-like cells pre-existed in the YLR102 untreated tumor. (A) IHC 
staining for ASCL1 on untreated and residual tumor sections of YLR102. Red arrow heads point to the 
nuclei stained as positive. Scale bar: 100μm. (B) Quantification of ASCL1 staining in YLR102. 
Significance for IHC staining quantification was determined by unpaired t-test between untreated and 
residual groups. Each group contains six different fields of view. ****: p<0.0001. (C-D) UMAP plots 
showing clustering of YLR102 untreated and residual tumor cells by single-cell RNA-sequencing. (E-
G) Feature plots depicting expression of ASCL1-related genes in individual cells. (H) Number of 
untreated and residual tumor cells in each individual cluster. Cluster 2 is highlighted in red frame. (I) 




Figure 3.3 ASCL1 overexpression caused TKI tolerance in HCC827 cell line. (A) Immunoblotting 
for ASCL1 in HCC827 cells transfected with empty vector or ASCL1 vector, upon doxycycline 
treatment with dose escalation. (B) Clonogenic assay for HCC827-EV or -ASCL1 cells treated with 
different concentrations of osimertinib for 10 days. (C) Quantification of colony number in (B). 
Significance was determined by multiple t-test. n=3 technical replicates for each condition. **: p<0.01; 
****: p<0.0001. (D) Drug sensitivity assay measuring readout of CellTiter Blue for HCC827-EV and -







Figure 3.4 ASCL1 expression led to EMT phenotype in permissive cellular contexts. (A) 
Morphology of PC9 and HCC827 cells transfected with EV or ASCL1. Scale bar: 100μm. (B) 
Expression level of EMT marker genes in PC9 and HCC827 with or without ASCL1 overexpression, 
treated with or without osimertinib. Significance was determined by unpaired t-test. n=3 technical 
replicates for each condition. n.s.: p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001. 
V=vehicle-treated; O=osimertinib-treated at 100nM for 3 days; P=persister after 10 days of osimertinib 
treatment at 100nM. (C) GSEA results showing the enrichment of EMT gene signature in untreated 
HCC827-ASCL1 cells compared to HCC827-EV cells; HCC827-ASCL1 persister cells compared to 
untreated HCC827-ASCL1 cells; and untreated PC9-ASCL1 cells compared to PC9-EV cells. 
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  Figure 3.5 TKI resistant EGFR-driven LUAD with SCLC transformation exhibited heterogeneous 
expression of subtype-defining transcriptional regulators of SCLC. (A-B) Mutational and copy 
number status RB1 and TP53 in SCLC transformation cases. (C-F) H&E staining (C) and IHC staining 




Histological transformation such as SCLC transformation and EMT are well-established 
mechanisms of TKI resistance and have been reliably observed in lung cancer patients 
receiving EGFR TKIs. The factors that determine which subset of patients undergo this 
phenotypic change and the detailed evolutionary process through which lineage transition is 
developed remain poorly understood. Investigating the cellular and molecular features of drug 
tolerant residual disease provides an opportunity to understand resistant mechanisms more 
comprehensively. Through transcriptomic profiling of residual tumors in our PDX models, we 
identified upregulation of ASCL1 in persistent tumor cells compared to untreated cells in one of 
the PDXs. ASCL1 is an important regulator of NE differentiation in SCLC however NE markers 
did not show enrichment in drug tolerant persister cells (Figure S3.1) and the residual tumor 
retained histology of adenocarcinoma without NE features (Figure 2.1F), suggesting that 
lineage transition did not occur in residual tumor cells despite increased expression of ASCL1. 
Previous genetic analyses of EGFR mutant lung cancer with SCLC transformation revealed a 
common RB1 loss, which is consistent with our patient cohort (Figure 3.5A). The expression of 
RB1 appeared to be intact in YLR102 PDX in which ASCL1 upregulation was identified given 
that it did not harbor any RB1 mutation and this gene was normally transcribed as indicated by 
RNA-seq. Therefore, additional genetic or epigenetic alterations may be required to trigger 
histological transformation. Ongoing work is focused on determining whether RB1 loss is 
required for NE phenotype to be manifested through knockout of RB1 in PDX and cell lines of 
mutant EGFR-driven lung cancer in the presence of ASCL1. 
Through in vitro assays for TKI sensitivity, we determined the role of ASCL1 in driving 
osimertinib tolerance in established human lung cancer cell lines. ASCL1 caused TKI tolerance 
by inducing an EMT signature specifically in HCC827 but not in the other lines, suggesting that 
cellular context can affect the lineage transforming function of ASCL1. Indeed, ASCL1 functions 
as a pioneer transcription factor to reprogram various cell types into neuronal cells only in the 
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presence of permissive epigenetic landscape [95]. Given the tendency of the HCC827 cell line 
to undergo EMT upon resistance to osimertinib, the current working hypothesis is that the genes 
encoding EMT-related regulators and markers are more accessible in this line compared to the 
others. To determine the chromatin accessibility for EMT-related genes in the human LUAD cell 
lines with or without ASCL1 overexpression, we are performing Assay for Transposase-
Accessible Chromatin using sequencing (ATAC-seq) for HCC827 and PC9 cell lines in different 
conditions to address the complexity of permissiveness underlying ASCL1-induced EMT. 
Intratumoral heterogeneity plays a critical role in the development of acquired resistance to 
targeted therapies. At the genetic level, subpopulations harboring resistance-conferring 
mutations quickly adapt to drug treatment and becomes the dominant clone in relapse tumor 
[50, 59, 60]. At transcriptional level, cells in a pre-existing drug tolerant state can survive 
treatment and be enriched in residual disease, which further evolves into acquired resistance 
[70]. In the mutant EGFR lung cancer PDXs that we examined in this study, transcriptional 
changes appeared to be the major contributor to TKI tolerance and single cell RNA-seq 
revealed pre-existing DTRC-like subclones, supporting the hypothesis of subclonal selection. 
One question that remains to be answered is whether adaptation to osimertinib may have any 
effect on the drug tolerant phenotypes. Despite the fact that the results of scRNA-seq clearly 
support the hypothesis of selection, we cannot exclude that adaptive changes induced by 
osimertinib may also be occurring and conferring drug tolerance. Future studies combining 
intricate cell barcoding technology and NGS may facilitate the efforts to track down the cell fate 




All of the human lung adenocarcinoma cell lines (PC9, H1975 and HCC827) and 293T/17 
cell line used in my thesis research were purchased from ATCC. The LUAD cell lines were 
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cultured in RPMI 1640 medium (gibco, 11875-093) supplemented with 10% fetal bovine serum 
(gibco, 16140-071), 1mM sodium pyruvate (gibco, 11360-070), 10mM HEPES (gibco, 15630-
080), 100U/ml penicillin and 100ug/ml streptomycin (gibco, 15140-122). 293T cells were 
cultured in DMEM medium (gibco, 11965-092) supplemented 10% FBS, 1mM sodium pyruvate, 
100U/ml penicillin and 100ug/ml streptomycin. Cells involved in doxycycline induction 
experiments were cultured with tet system approved FBS (Takara Bio, 631101) instead. Cells 
were frozen down in FBS plus 10% DMSO (AmericanBio, AB00435-00500) for preservation. 
 
Immunohistochemistry staining. 
Experimental details are the same as described in chapter 2.  
Primary antibodies used for IHC: ASCL1 (abcam, ab211327, 1:500), NEUROD1 (abcam, 
ab213725, 1:1000), YAP1 (CST, 14074, 1:400). 
 
Western blotting. 
Experimental details are the same as described in chapter 2.  
Primary antibodies used for western blotting: ASCL1 (abcam, ab211327), BCL2 (CST, 
4223), DLL3 (CST, 71804), RET (CST, 14556), Nkx2-1 (abcam, ab76013), EpCAM (abcam, 
ab32392), Vimentin (CST, 5741). All the primary antibodies were diluted in 5% non-fat dry milk 
by 1:1000, unless stated otherwise. 
 
Bulk RNA-sequencing.  
Experimental details are the same as described in chapter 2.  
 
RNA-seq data analysis. 
RNA-seq raw data generated from human cell lines were trimmed of adaptor sequences 
using Trim Galore (v0.5.0, https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and 
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mapped to the human reference genome (hg38) using HISAT2 [99]. The sequencing reads 
were annotated according to GENCODE v27 model and gene expression levels were quantified 
using StringTie [100]. Differentially expressed genes were identified using DESeq2 [80]. 
 
Pathway enrichment analysis. 
Experimental details are the same as described in chapter 2. 
 
Gene Set Enrichment Analysis.  
Experimental details are the same as described in chapter 2. ASCL1 gene signatures were 




Subcutaneous PDX tumors were resected from mice and processed with tumor dissociation 
kit. The single-cell suspension was stained with human EpCAM antibody (BioLegend, 324209, 
1:100) and LIVE/DEAD cell stain (invitrogen, L34971, 1:250), and subjected to FACS to isolate 
live tumor cells, based on the gating strategy shown in Figure S3.2A. The sorted cells were re-
suspended in FACS buffer and loaded on the Single Cell A Chip together with RT Master Mix 
and barcoded gel beads to form nanoliter-scale Gel Beads in Emulsions (GEMs) through 
Chromium Controller. The single-cell cDNA libraries were constructed using 3’ library prep kit v3 
(10X genomics) and then sequenced on illumina HiSeq4000 sequencer using 100bp pair-end 
sequencing to generate approximately 150M reads per sample. 
 
Single-cell RNA-seq data analysis. 
The single-cell sequencing raw data were processed and mapped to a human-mouse hybrid 
genome to distinguish between human and mouse cells. Then gene expression matrix for 
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human cells is generated by Cell Ranger pipeline and analyzed using Seurat package (v3.0) in 
R language [101, 102]. Genes whose expression was identified in at least three cells would be 
considered as features and cells with number of feature genes greater than 200 but smaller 
than 7000 and percentage of mitochondria reads less than 50% were included in the following 
analyses. The single-cell expression data were normalized by SCTransform embedded in 
Seurat v3 and then underwent linear dimensional reduction through PCA. The first 100 principal 
components were used to cluster cells, with a resolution of 0.4. The clustering results were 
visualized with UMAP plot. Expression level of individual genes was visualized with feature plots 
and heatmaps. 
 
ASCL1 overexpression in human LUAD cell lines. 
Human ASCL1 cDNA was amplified from phASCL1-N106 (addgene, #31781) with Q5 HF 
master mix (NEB, M0492S), ASCL1_F and ASCL1_R, and purified with Monarch PCR & DNA 
Cleanup Kit (NEB, T1030S). Cleavage sites for NheI (NEB, R3131S) and AgeI (NEB, R3552S) 
were added to both ends during PCR. After digestion of the PCR products and pCW57-MCS 
empty vector (addgene, #71782) with both restriction enzymes and purification of the digestion 
products, ASCL1 cDNA insert was ligated to plasmid backbone using T4 DNA ligase (NEB, 
M0202S). The ligation products were transfected into stbl3 competent E. coli (invitrogen, 
C7373-03) and bacteria were spread on ampicillin LB agar plate. Single clones were cultured in 
LB broth (gibco, 10855-021) with 100ug/ml ampicillin (AmericanBio, AB00115-00010) overnight 
and plasmids were extracted by QIAprep spin miniprep kit (Qiagen, 27106). Successful ligation 
was confirmed by sanger sequencing using the sequencing primer. 
The pCW57-hASCL1 vector and empty vector were then packaged into lentivirus with 
TransIT-Lenti reagent (Mirus Bio, MIR6604). Target vectors and two packaging plasmids – 
pMD2.G (addgene, #12259) and psPAX2 (addgene, #12260) were transfected into 293T cells 
following instructions of TransIT-Lenti. Lentivirus-containing cell medium was collected 2 days 
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following transfection and ran through 0.45um filter (Millipore, SLHV033RS) to remove cell 
debris. Lentivirus was concentrated through ultracentrifugation at 18000rpm, 4 degree for 2h 
and resuspended with PBS. Lentiviral particles were added to cell medium one day after cell 
seeding, supplemented with 8ug/ml TransduceIT reagent (Mirus Bio, MIR6620) to facilitate 
infection. Lentivirus-infected cells were treated with puromycin (gibco, A11138-03) at 
appropriate concentrations (0.7ug/ml for PC9 and 0.5ug/ml for H1975 and HCC827) for one 
week to generate stable cell lines. 
Cells transfected with EV or ASCL1 vector were maintained in RPMI 1640 cell medium 
supplemented with 10% tet system-certified FBS and 1ug/ml doxycycline (Sigma-Aldrich, 
D9891), unless stated otherwise. 
Primers used in this section are listed here. ASCL1_F: 5’-AGCTAGCGCGGCCGCCACC-3’. 
ASCL1_R: 5’-GACCGGTTCGCGATCTAGA-3’. Sequencing primer for pCW57-hASCL1: 5’-
CGTATGTCGAGGTAGGCGTG-3’.  
All the plasmids were obtained from Addgene. phASCL1-N106 was a gift from Jerry 
Crabtree (Addgene plasmid # 31781). pCW57-MCS1-2A-MCS2 was a gift from Adam Karpf 
(Addgene plasmid # 71782). pMD2.G and psPAX2 were gifts from Didier Trono (Addgene 
plasmid # 12259 and 12260). 
 
Clonogenic assay. 
Cells were seeded with doxycycline in 6-well plates and treated with drug vehicle or 
Osimertinib at various concentrations for 10 days. Seeding density is 250 cells/well for H1975 
EV/ASCL1 cells and 500 cells/well for the other cell lines. Cell medium containing drugs was 
replenished every three days. Cell clones formed in the absence or presence of osimertinib 
were fixed with 4% PFA and stained with crystal violet (Sigma-Aldrich, C3886). Tissue culture 
plates were then washed with water to remove excess stain and dried for pictures and 
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quantification. Osimertinib was dissolved in DMSO and final concentration of drug vehicle was 
no more than 1:1000 in cell culture medium. 
 
Drug sensitivity assay. 
Cells were seeded with doxycycline in 96-well plates and treated with drug vehicle or 
Osimertinib at escalating concentrations for 3 days. Seeding density is 3500 cells/well for PC9 
EV/ASCL1 cells, 3000 cells/well for H1975 EV/ASCL1 cells, 3500 cells/well for HCC827 EV 
cells and 2500 cells/well for HCC827 ASCL1 cells. Cell viability was determined with CellTiter 
Blue reagent (Promega, G8081) following manufacturer’s protocol. Fluorescence was measured 






Figure S3.1 YLR102 residual disease did not show histological transformation into SCLC. The 
table showed the RPKM value of individual NE marker genes and SCLC subtype identifiers in each of 
the YLR102 samples as well as the log2-scaled fold change in gene expression in residual disease 




Figure S3.2 Human tumor cells were enriched for single-cell RNA-sequencing by FACS. (A) 
Experimental scheme. (B) Expression of lung epithelial markers in EpCAM+ and EpCAM- cells sorted 
from YLR102 PDX. (C) Expression level of EPCAM in untreated and residual tumors of YLR102.  
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  Figure S3.3 DTRC-like tumor cells pre-existed in untreated YLR074 PDX. (A) UMAP plots showing 
clustering of YLR074 untreated and residual tumor cells by single-cell RNA-sequencing. (B) Number of 




  Figure S3.4 ASCL1 overexpression did not affect osimertinib sensitivity in PC9 or H1975 cell 
lines. (A-B) Immunoblotting for ASCL1 in (A) PC9 and (B) H1975 cells transfected with empty vector 
or ASCL1 vector, upon doxycycline treatment with dose escalation. (C-D) Clonogenic assay for EV or 
ASCL1 transfected (C) PC9 and (D) H1975 cells treated with different concentrations of osimertinib for 
10 days. (E-F) Drug sensitivity assay for (E) PC9-EV/ASCL1 and (F) H1975-EV/ASCL1 cells when 







Figure S3.5 ASCL1 expression led to EMT phenotype in permissive cellular contexts. (A) PCA 
plot visualizing the gene expression profiles of different experimental groups. (B) Immunoblotting of 
epithelial and mesenchymal markers in PC9 and HCC827 cell lines following ASCL1 overexpression. 
(C) Expression level of SNAI and TWIST transcription factors in PC9 and HCC827 cells under different 
experimental conditions. (D) Expression of epithelial and mesenchymal markers in untreated and 
residual tumors in YLR074 and YLR102 revealed by RNA-seq. Significance was determined by 
unpaired t-test. n=2 biological replicates for untreated group and n=3 biological replicates for residual 
group. n.s.: p>0.05; *: p<0.05; ***: p<0.001. 
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  Table S3.1 Top 5 upregulated pathways in HCC827 and PC9 cells after ASCL1 overexpression 




Table S3.2 Expression level of NE markers and subtype-defining transcriptional regulators of 
SCLC in pre- and post-TKI EGFR-driven lung cancer. The table showed the FPKM value of 
individual NE marker genes and SCLC subtype identifiers in patient specimens obtained from pre-TKI 
(YUL0025P) and TKI-resistant SCLC-transformed tumors (YUL0025R) from the same patient. 
Expression levels of dramatically upregulated genes were highlighted in red for post-TKI tumor 
sample. 
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PDX models serve as critical tools for understanding drug tolerant residual disease from a 
clinical perspective given that these preserve a number of biological traits of patient specimens. 
However, the lack of a functional immune system in an NSG mouse host results in a defective 
interaction between tumor cells and the microenvironment. To gain more comprehensive 
knowledge about TKI tolerance in an immunocompetent system, we performed complementary 
research using a refined genetically-engineered mouse model (GEMM), in which lung tumor 
cells are labeled with the fluorescent marker mKate to enable cell sorting. We characterized 
multiple aspects of this model, including tumor development, histology, response to EGFR TKIs 
and isolation of untreated and residual tumor cells. Gene expression profiling of mKate+ cells 
sorted from tumor bearing mice with or without osimertinib treatment revealed common 
pathways that are deregulated in both GEMM and PDX models. 
 
INTRODUCTION 
Cancer can be modeled both in vitro as 2D or 3D cultures and in vivo with tumors growing in 
experimental animals. In chapter 2 and 3, we discussed our studies on drug tolerant residual 
disease in PDX models, which provided insights into the mechanisms of drug tolerance in a 
clinically-relevant setting. In order to reduce graft rejection and ensure successful engraftment 
of human tumor tissues in a murine system, the mouse hosts are engineered to have a severe 
immune deficiency [103, 104]. The lack of a functional immune system in PDXs means that 
interactions between tumor cells and immune cells in the microenvironment are not 
recapitulated in these models. Furthermore, in most PDX models, tumor cells are grown 
subcutaneously rather than in the organs where patient biopsies were obtained. Therefore these 
models do not fully represent tumor development and drug response in the most physiologically-
relevant conditions. In order to gain comprehensive knowledge about mechanism of TKI 
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tolerance in EGFR mutant lung cancer, we performed complementary studies on the biology of 
tumor cells in an immune-competent genetically-engineered mouse model. 
Transgenic mice have been widely used to study the biology and drug resistance of EGFR 
mutant lung adenocarcinoma [23, 53, 105]. Transgenes encoding oncogenic drivers are 
integrated into the mouse genome and their expression is induced specifically in lung epithelial 
cells using a doxycycline-inducible genetic approach, resulting in transformation of healthy lung 
epithelial cells into lung adenocarcinoma cells. The mouse tumors therefore develop 
orthotopically in the lungs in the presence of the lung microenvironment and tumor-bearing mice 
can be used to study the biology of the tumors, therapeutic responses, drug resistance and, 
importantly for this project, drug tolerant persister cells.  
GEMMs have been successfully used to model acquired resistance to EGFR TKIs and 
identify resistance mechanisms. In general, the tumor-bearing mice respond quite well in the 
beginning of TKI treatment and the mouse lungs appeared to be normal through imaging and 
histological analysis, however, TKI resistant tumor nodules develop after a prolonged and 
continuous treatment [23, 106], indicating the presence of drug tolerant residual cells despite 
the almost complete drug response. 
In this chapter, we refined and characterized a GEMM of EGFR-driven lung cancer such that 
cancer cells were labeled with the fluorescent protein mKate that enabled them to be sorted. 
mKate+ cells isolated from untreated and treated mice can be genetically and transcriptionally 
profiled to identify mechanisms of drug tolerance. Although tumor-bearing mice showed an 
almost complete response to osimertinib, mKate+ cells were still present following TKI 
treatment. Through targeted deep sequencing, we did not find any EGFR mutations in the 
residual cells that are known to confer resistance. Comparison of the gene expression profile 
between untreated and residual cells revealed some gene signatures that were shared between 
residual diseases identified in PDX models and GEMM as well as features that were unique to 




Identification and isolation of drug tolerant residual cells in a GEMM of EGFR mutant 
lung cancer. 
To induce the expression of mutant EGFR and label tumor cells with a fluorescent marker, 
we crossed mice carrying a doxycycline-inducible mutant EGFR transgene with a conditional 
allele that encodes the rtTA transcriptional activator and red fluorescent protein mKate that were 
expressed upon deletion of a lox-stop-lox cassette by Cre recombinase [107]. A CreER 
transgene was under control of Sftpc promoter, which enabled the expression of recombinase 
specifically in type II alveolar lung epithelial cells in a tamoxifen inducible manner [108]. 
Additionally, a Trp53 floxed allele is incorporated into the model to accelerate tumor 
development and increase the aggressiveness of tumor cells [109, 110]. Mice of the appropriate 
genotype (Figure 4.1A-B) were administered tamoxifen to activate CreER recombinase, which 
initiated rtTA and mKate expression and deleted Trp53 gene in lung epithelial cells. Mice were 
then fed with a doxycycline diet to induce expression of the EGFR L858R mutant, which drove 
transformation of healthy lung epithelial cells into lung adenocarcinoma cells. Theoretically, all 
the cells that express mutated EGFR would be labeled with mKate and can be isolated through 
FACS. 
To verify tumor development, we monitored the tumor volume in mouse lungs by magnetic 
resonance imaging (MRI). Typically, after 6-10 weeks on a DOX diet and initial tamoxifen 
treatment, mice developed diffused tumor lesions in the lungs that were responsive to both the 
first generation TKI erlotinib and third generation TKI osimertinib (Figure 4.1C-D and S4.1A-B). 
The lung tumors regressed almost completely after treatment with osimertinib for 4 weeks and 
the histology of the lungs of TKI-treated mice reverted from harboring lung adenocarcinomas to 
looking histologically normal and similar to those in healthy mice (Figure 4.1E and S4.1C). In 
contrast, tumor bearing mice only showed partial responses to erlotinib in most cases (Figure 
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S4.1C), indicating a more potent anti-tumor effect of osimertinib compared to erlotinib. Whether 
this reflects a difference in the ability of the TKIs to inhibit EGFR in this model remains to be 
determined. 
One of the advantages of this transgenic mouse model is expression of fluorescent marker 
in lung epithelial cells, including tumor cells. To validate expression of mKate and confirm the 
presence of drug tolerant residual cells in mice with complete tumor regression, we probed for 
mKate+ cells in mouse lungs before and after osimertinib treatment by IHC staining and FACS. 
Pre-treatment tumor cells showed strong positivity for EGFR mutant and mKate (Figure 4.2A). 
The mKate+ cells could also be detected by flow cytometry both before and after osimertinib 
treatment (Figure 4.2B-C) despite the absence of sizable post-treatment tumor lesions as 
revealed by MRI and histological analysis (Figure 4.1C-E). To determine the appropriate time 
point to collect DTRCs, we treated tumor-bearing mice with osimertinib for 4 or 6 weeks until the 
tumors were no longer visible and compared the number of mKate+ cells isolated from mouse 
lungs between the two groups. There was no significant difference between the 4- and 6-week 
groups, indicating that maximal tumor regression had been achieved by week 4 on drug (Figure 
4.2B). Therefore, we collected mKate+ cells after 4 weeks of osimertinib treatment. Besides 
mKate+ cells isolated from TKI-naïve and treated mice, we were also able to collect them from 
healthy mice that do not harbor mutant EGFR transgene through sorting (Figure 4.2B and 
4.3A). The cellular profiling of the lung tumors suggests that tumor cells still persist even after 
they become undetectable by imaging and the DTRCs, although few in number, can be 
collected through FACS.  
 
Transcriptional profiling of the tumor cells isolated from the pre- and post-treatment 
GEMM revealed pathways deregulated in DTRCs. 
In order to identify the mechanisms that drive TKI tolerance in the GEMM, we sought to 
investigate and compare the molecular features of untreated tumor cells and drug tolerant 
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persisters. As GEMMs of mutant EGFR lung cancer are often used to study on-target 
mechanisms of acquired resistance to EGFR TKIs [23, 106], our first step for this molecular 
profiling was to search for mutations in EGFR that conferred resistance to first-, second- and 
third-generation TKIs in pre- and post-treatment tumor cells isolated from the GEMM (Figure 
4.3A). We performed targeted deep sequencing for the EGFR coding regions that covered the 
codons that were known to be mutated and cause acquired resistance, including L718V/Q, 
T790M and C797S [23-27]. We also examined the presence of the EGFR L858R mutation 
encoded in the transgene as positive control to ensure proper sequencing and data analysis. 
The common drug resistant EGFR mutations were not detected in treatment-naïve, osimertinib-
treated or erlotinib-treated tumor cells whereas the L858R mutation was uniformly present 
(Figure S4.2), suggesting that resistance conferring mutations in EGFR were not the major 
contributors to the drug tolerant phenotypes in the TKI-treated GEMM. 
Since on-target genetic mechanisms were not identified in post-osimertinib mKate+ cells, we 
then went on to profile the transcriptomic changes in mKate+ cells after 4 weeks of osimertinib 
treatment versus mKate+ cells prior to TKI treatment. We sorted mKate+ cells from TKI naïve 
and long-term osimertinib treated (4 weeks) tumor bearing mice, as well as from healthy mice in 
which lung epithelial cells were labeled with mKate but lacked mutant EGFR expression (Figure 
4.3A). Bulk RNA-seq of mKate+ cells collected from healthy, untreated and osimertinib-treated 
mice revealed dramatic differences in gene expression between the three groups (Figure 4.3B). 
This result further indicates that mKate+ cells isolated from healthy mice and tumor bearing 
lungs following complete response to osimertinib were not transcriptionally identical despite the 
similar histology shared by healthy tissue and osimertinib treated lung tissue (Figure 4.1E). The 
expression level of lung epithelial markers was largely retained across different conditions, 
indicating the isolation of correct cell types through mKate sorting (Table 4.1). In order to 
systematically analyze the gene expression profiles, we performed the MetaCore pathway 
analysis for the bulk RNA-seq data of mKate+ cells to identify the pathways that were potentially 
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altered in post- vs pre-treatment mKate+ cells. Such analyses revealed transcriptional programs 
that were positively or negatively enriched in osimertinib-treated mKate+ cells compared to 
untreated counterparts. Top pathways that were upregulated in post-treatment cells included a 
lipid biosynthesis pathway mediated by SREBP and development-related NOTCH pathway. The 
functional and mechanistic implications of these pathways remain to be studied in order to 
address how they are related to TKI tolerance. The downregulated pathways in mKate+ cells 
following osimertinib treatment were mainly centered in cell cycle and target genes of HIF-1α 
(Figure 4.3C). It is worth noting that similar programs were also implicated in pathway analysis 
for residual tumor cells in our PDX models, including upregulation of development-related 
pathways such as Wnt signaling and Hedgehog signaling and downregulation of cell cycle-
related pathways and HIF-1α activity (Figure S2.5A-B). The commonality between GEMM and 
PDX models suggests that signaling networks critical for normal growth and development may 
be hijacked by residual tumor cells to promote survival and that treatment-induced cell cycle 






  Figure 4.1 Tumor-bearing transgenic mice of mutant EGFR LUAD showed complete responses 
to osimertinib. (A) Transgenic composition of the GEMM used for study of drug tolerance. (B) 
Experimental schema for tumor development and TKI treatment. (C) Tumor burden in osimertinib-
treated mice as measured by MRI. (D) MRI images of pre- and post-treatment mouse lungs. (E) H&E 
staining showing the histology of the lungs from treatment-naïve, osimertinib-treated and healthy mice. 




Figure 4.2 Isolation of mKate+ cells from the GEMM. (A) IHC staining for EGFR L858R mutant and 
mKate. Scale bar: 50μm. (B) Number of mKate+ cells isolated from tumor-bearing mice after 
osimertinib treatment for 4 or 6 weeks and from healthy mice. (C) Flow charts showing the presence of 
mKate+ cells in mouse lungs both before and after treatment. The genotypes and drug treatment 




Figure 4.3 Transcriptomic profiling of mKate+ cells isolated from the GEMM. (A) Experimental 
schema for molecular profiling of mKate+ cells isolated in various conditions. (B) PCA plot showing the 
differences in gene expression profiles of mKate+ cells between healthy, untreated and osimertinib-
treated groups. (C) Results of MetaCore pathway analysis showing the pathways up- or 
downregulated in osimertinib-treated mKate+ cells as compared to untreated cells. 
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DISCUSSION 
The transgenic mouse model of mutant EGFR lung cancer provides further insights into 
mechanisms of TKI tolerance, which are complimentary to the PDX models as discussed in 
Chapter 2 and 3. We performed different types of NGS for the tumor cells collected from the two 
models and profiled the molecular properties of drug tolerant residual disease in vivo. One 
prominent feature identified through DNA sequencing that is shared across different mouse 
models is lack of resistance conferring mutations in both pre- and post-TKI treatment tumor 
cells. In PDXs, we identified neither osimertinib resistant mutations in EGFR that emerged 
following treatment nor any dramatic changes in allelic frequency of already existing mutations 
in residual disease compared to untreated tumors. In GEMMs, there was no selection or 
enrichment of common mutations in EGFR transgene that cause resistance to first-, second- or 
third-gen TKIs in DTRCs. These results suggest that at least in the models that we have 
examined, TKI resistant mutations, if any, tend to develop de novo during treatment rather than 
pre-exist in treatment-naïve tumors. To support this idea, studies of acquired resistance to 
osimertinib in GEMMs suggest that it generally takes 5-6 months to obtain resistant tumor 
nodules [23] and 4 weeks of TKI treatment is probably not sufficient for observing a dominant 
clone with secondary mutations. The PDX models (YLR074 and YLR102) require even longer 
period of treatment to develop acquired resistance. Pilot studies suggest that tumors were still 
sensitive to osimertinib following treatment for about a year with drug-on and -off schedule. 
Therefore, TKI resistant mutations are unlikely to be present at high frequency in persistent 
tumor cells after only six weeks of treatment. Furthermore, in vitro analyses of human mutant 
EGFR lung cancer cell lines indicated the presence of a subpopulation free of pre-existing drug 
resistant T790M mutation, which developed acquired resistance and gained T790M mutation 
after long-term treatment with first-gen EGFR TKI, indicating the possibility of de novo 
mutagenesis given enough time of drug treatment [50]. 
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In the DTRCs isolated from GEMM, we identified an upregulated transcriptional program 
that was related to cholesterol and fatty acid biosynthesis and controlled by the transcription 
factor SREBP. This finding led to a hypothesis that changes in metabolic pathways could be 
underlying the drug tolerant phenotypes in tumor cells. In fact, metabolic reprogramming has 
been characterized in residual tumor cells following oncogene deprivation in transgenic mouse 
models of breast cancer [111]. The tumor cells that persisted after cessation of oncogene 
expression shifted to lipid metabolism, which resulted in production of higher levels of reactive 
oxygen species (ROS) and altered redox balance within the cells. The metabolic shifts caused 
increased accumulation of DNA damage mediated by ROS and eventual tumor recurrence. In 
order to understand how SREBP-related transcriptional changes shape the metabolic status in 
drug tolerant persisters, future experiments will be focused on profiling the regulators and 
enzymes in different metabolic pathways to determine the relationship between metabolic 
reprogramming and survival of DTRCs. 
The Cre recombinase-mediated conditional rtTA expression system in this refined GEMM 
can be adapted in various ways. When combined with lentiviral-Cre and other genetic tools, this 
model enables direct genetic modifications and cell barcoding in mouse lung tumor cells. 
Recent CRISPR screening studies in the GEMM of mutant EGFR lung cancer revealed the 
possibility to edit multiple tumor suppressor genes simultaneously and compare tumor 
development and TKI responses in different genetic contexts [110]. A refined model like this is 
useful in terms of investigating the biology of drug tolerant persisters in the presence of various 
co-occurring mutations identified in lung cancer patients. 
In the GEMM that we discussed in this chapter, we identified mKate+ cells in tumor-bearing 
mice with complete responses to osimertinib. One potential problem with this model, especially 
when drug response is profound and tumor lesion is invisible, is that mKate-expressing cells 
may not be transformed and retain the phenotypes of healthy epithelial cells. In the context of 
drug tolerant residual disease, these mKate+ normal cells can be sorted out together with 
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persister tumor cells, confounding the molecular profiling studies of drug tolerant mechanisms. 
A potential solution to this problem is to perform single-cell sequencing on the isolated mKate+ 
cells to distinguish between healthy and tumor cells and to untangle the complexity resulting 
from a mixed cell population. 
 
EXPERIMENTAL PROCEDURES 
Initiate tumor growth in the GEMM. 
6-8 weeks old mice with appropriate genotypes were given two consecutive doses of 
tamoxifen (Sigma-Aldrich, C5648) at 0.25mg/g to active Cre recombinase. Mice were then fed 
with doxycycline diet (Envigo) to induce expression of oncogenic EGFR. Tumor development 
was monitored by MRI until the mice were ready to be treated. 
Tamoxifen was dissolved at 25mg/ml in corn oil (Sigma-Aldrich, C8267), with overnight 
shaking. 
 
Drug treatment in vivo. 
Tumor-bearing mice were treated with osimertinib at 25mg/kg for five consecutive days each 
week when their tumor size reached around 300-500mm3. The treatment lasted for 4 weeks 
before mouse lungs harboring drug tolerant residual tumor was excised. Tumor burden was 
measured by MRI at least once before treatment and once before sacrifice. 
 
Magnetic resonance imaging. 
Experimental details of magnetic resonance imaging on mice were described previously 
[112]. In brief, mice were anesthetized and maintained on isoflurane/O2 (2–2.5% v/v) 
throughout the imaging process. MR images were collected using a 4T small-animal Bruker 
horizontal-bore spectrometer (Bruker AVANCE). MR data collection was synchronized with 
animal respiration through a small-animal monitoring and gating system (SA Instruments, Inc), 
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to make sure that all the images were captured during postexpiratory periods. Tumor burden 
was determined by quantification of lung opacity area present in MR images using BioImage 
Suite 3.01 [113].  
 
Immunohistochemistry staining. 
Experimental details are the same as described in chapter 2. 
Primary antibodies used for IHC: EGFR L858R mutant (CST, 3197, 1:100), mKate (Evrogen, 
AB233, 1:1000). 
 
Sorting of mKate+ cells. 
Mouse lungs excised from mice with desired genotypes and receiving appropriate 
treatments were processed with mouse lung dissociation kit (Miltenyi Biotech, 130-095-927). 
The single-cell suspension was subjected to FACS to identify and isolate mKate+ cells, based 
on the gating strategy shown in Figure 4.2C.  
 
Targeted deep sequencing for EGFR transgene. 
Genomic DNA was extracted from sorted mKate+ cells with AllPrep DNA/RNA Micro Kit 
(Qiagen, 80284) and used as template to amplify two coding regions in mutant EGFR 
transgene: cDNA 2065-2355 and 2337-2604, which cover the common TKI resistant mutations 
in EGFR kinase domain. The PCR was performed with HotStarTaq Master Mix Kit (Qiagen, 
203443). Sequencing libraries were prepared from PCR products with KAPA HyperPrep Kit 
(Kapa Biosystems, KK8504), KAPA Dual-Indexed Adapter Kit (Kapa Biosystems, KK8722), and 
KAPA Pure Beads (Kapa Biosystems, KK8000). The libraries were pooled and sequenced on 
illumina NovaSeq 6000 sequencer at YCGA to generate 150bp paired end reads. The raw 
sequencing reads were first aligned to the EGFR amplicon sequences using the Burroughs-
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Wheeler aligner [72], and an in-house script was used to calculate the allelic frequency at each 
position seen in the amplicon reference. 
 
Bulk RNA-sequencing.  
Total RNA was extracted from sorted mKate+ cells with AllPrep DNA/RNA Micro Kit 
(Qiagen, 80284). RNA integrity was determined by running an Agilent Bioanalyzer gel, which 
measures the ratio of the ribosomal peaks. Samples with RIN values of 7 or greater proceeded 
to library prep. RNA-seq libraries were constructed using SMART-Seq v4 Ultra Low Input RNA 
Kit (Takara Bio) and sequenced on illumina HiSeq2500 sequencer using 75bp single-end 
sequencing to generate around 30M reads per sample. 
 
Bulk RNA-sequencing data analysis. 
Low quality reads were trimmed and adaptor contamination were removed using Trim 
Galore (v0.5.0, https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Trimmed 
reads were mapped to the mouse reference genome (mm10) using HISAT2 (v2.1.0) [99]. Gene 
expression levels were quantified using StringTie (v1.3.3b) [100] with annotations based on 
gene models (vM15) from the GENCODE project. Differentially expressed genes were identified 
using DESeq2 (v 1.22.1) [80]. 
 
Pathway enrichment analysis. 





Figure S4.1 Tumor-bearing transgenic mice of mutant EGFR LUAD showed partial responses to 
erlotinib. (A) Tumor burden in erlotinib-treated mice as measured by MRI. (B) MRI images of pre- and 
post-treatment mouse lungs. (C) Waterfall plot showing the degree of drug response in osimertinib- 




Figure S4.2 On-target resistance conferring EGFR mutations were not enriched in mKate+ cells 
isolated from TKI-treated GEMM. Bar plots showing the frequency of wildtype alleles at the codon 
encoding EGFR mutations known to confer resistance to first-, second- and third-generation EGFR 
TKIs in mKate+ cells sorted from untreated and TKI-treated mice. EGFR L858R mutation was 
analyzed as a positive control and the bar plot for L858R showed the frequency of mutant allele.  
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  Table S4.1 Expression of lung epithelial markers in mKate+ cells isolated from healthy, 
untreated and osimertinib-treated mice. 
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CLOSING REMARKS 
Incomplete response to therapies occurs in nearly all types of cancer. In many cases, tumor 
lesions in patients receiving anti-tumor agents initially undergo regression, followed by an 
intermediate drug tolerant stage where tumor burden remains constant as treatment continues 
with eventual tumor progression (acquired resistance). In mutant EGFR-driven lung cancer for 
which targeted therapy is available, residual disease is a major challenge since acquired 
resistance to EGFR TKIs is inevitable and the main reason for treatment failure. Studies on drug 
tolerant persisters in TKI-treated lung cancer cell lines have broadened our knowledge about 
the biology of persister cells in vitro. Further investigation of residual disease from a more 
clinically and physiologically relevant perspective will deepen our understanding about drug 
tolerant mechanisms in vivo and shed light on the evolution of acquired resistance in more 
detail. To pursue this and gain insights into the biology of residual disease, we studied the 
biological properties of drug tolerant residual disease in PDX mouse models, which more 
resembled the complexity and diversity of clinical specimens than established cell lines.  
In the three PDXs that we characterized in my thesis project, two of them showed 
incomplete tumor regression in response to the third-generation TKI osimertinib, which 
mimicked the residual disease observed in mutant EGFR lung cancer patients receiving EGFR 
TKIs. The cellular features of persistent tumor cells included cell cycle arrest and low levels of 
apoptosis, as evidenced by IHC staining for proliferation and apoptosis markers. To identify 
mechanisms underlying TKI tolerance in DTRCs, we examined the genomic and transcriptomic 
profiles of residual tumor cells and explored the changes in the mutational landscape and gene 
expression before and after osimertinib treatment. As indicated by WES, the mutational 
landscape remained very similar between untreated tumor and residual disease. However, gene 
expression profiling revealed a number of differentially expressed genes in residual tumor cells 
compared to the untreated ones in both PDXs, indicating that transcriptional rather than genetic 
mechanisms potentially accounted for TKI tolerance in persister cells. 
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Close examination of gene expression data for PDX tumor samples led to identification of 
ASCL1 upregulation in one of the PDXs post-osimertinib treatment. Gene-set enrichment 
analysis suggested that ASCL1 functioned as a transcription factor and a gene signature 
associated with it was induced in the residual cells. To understand how the tumor cells evolved 
into DTRCs during TKI therapy, we performed single-cell RNA-sequencing for untreated and 
residual tumor cells, which revealed the presence of a pre-existing DTRC-like subpopulation in 
untreated tumors characterized by high expression of ASCL1. The intratumoral heterogeneity 
identified in PDXs raised the possibility that residual cells resulted from the selection of a 
subpopulation with drug tolerant state by EGFR TKIs.  
Subsequent functional and mechanistic studies demonstrate that ASCL1 overexpression led 
to osimertinib tolerance in one out of the three mutant EGFR lung adenocarcinoma cell lines 
that we tested. In the cell line that showed TKI tolerant phenotypes but not in the others, ectopic 
expression of ASCL1 induced morphological changes and an EMT gene signature, indicating a 
context-dependent role of ASCL1 in driving phenotypic changes in EGFR mutant lung cancer.  
In addition to studying PDX models, to get a more comprehensive understanding of 
mechanisms of TKI tolerance, we also interrogated the biological features of drug tolerant 
persister cells in an immune-competent GEMM of EGFR mutant lung cancer in which lung 
epithelial cells were labeled with fluorescent marker to enable FACS. Transcriptomic profiling of 
the mKate+ cells isolated from mice before and after TKI treatment by RNA-seq indicated a 
variety of deregulated gene expression programs in residual cells, which were involved in 
regulatory and survival pathways, including upregulation of cholesterol/fatty acid biosynthesis 
and NOTCH signaling pathway, as well as downregulation of cell cycle-related pathways and 
HIF1α-regulated program. Further studies to understand the biological implications of 
deregulation of these pathways remain to be performed. 
Despite all the in vivo and in vitro findings that lead to deeper insights into residual disease 
in EGFR-driven lung cancer, questions regarding the connections between drug tolerance and 
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acquired resistance and the therapeutic approaches to target residual tumor cells still remained 
to be addressed. 
 
Evolving from drug tolerant residual disease into acquired resistance. 
Five EGFR TKIs have been approved as the first-line treatment for EGFR mutant lung 
cancer, however acquired resistance inevitably occurs in patients receiving any of these drugs. 
On-target resistance conferring mutations in EGFR are the major mechanisms of resistance for 
all of the three generations of TKIs [30, 33, 34, 36]. Although previous studies have 
demonstrated that the T790M mutation, for example, can pre-exist in TKI-naïve tumors at low 
frequency and become enriched following treatment with first-generation TKIs, T790M- tumor 
cells can still survive TKI treatment as drug tolerant persisters and eventually develop such 
resistance mutation de novo [50]. Drug tolerant residual disease acts as an intermediate stage 
between pre-treatment tumor and acquired resistance and understanding its mutational 
landscape thus provides insights into how the resistance-conferring mutations come into 
existence. In either the PDX models or the GEMM that we studied in this thesis project, the on-
target EGFR mutations were not identified in residual tumor cells and the overall mutational 
landscape remained largely unchanged compared to untreated tumors. Indeed, increasing 
evidence suggests that TKI tolerance in EGFR mutant lung cancer is caused by epigenetic 
mechanisms and transcriptional changes rather than resistance conferring mutations [41, 44, 
47]. The absence of genetic drivers in TKI tolerant cells suggests that mutagenesis is a 
relatively inefficient process and it takes a long time for the right gene target to become mutated 
and for drug resistant clones to become dominant in recurrent tumors. In the mouse models 
described in previous chapters, the residual tumor cells were collected following only 1-2 
months of TKI treatment, which was likely to be still at an early stage considering the time frame 
during which acquired resistance usually developed (~1.5 years for osimertinib). Further 
characterization of residual tumor cells collected longitudinally along the treatment course would 
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provide more evidence to elucidate when certain resistance-associated genetic events occur in 
the genome. 
Phenotypic transition and histological transformation constitute another big category of 
mechanisms of TKI resistance, for which detailed evolutionary processes remain poorly 
understood. We identified upregulation of a neuroendocrine lineage factor ASCL1 in post-
osimertinib residual tumors from one of the PDX models that we examined, albeit without 
significant neuroendocrine phenotypes. Given the role of ASCL1 as a neuroendocrine lineage 
transcription factor, the residual disease in that PDX might represent a transition state prior to 
the acquisition of neuroendocrine features. RB1 has been implicated as being commonly 
mutated in TKI-resistant tumors with SCLC transformation [114]. Therefore, one hypothesis is 
that histological transformation requires the presence of additional genetic alterations like RB1 
loss and functional studies in PDX and cells are underway to prove this.  
 
Upstream regulators for ASCL1 in EGFR mutant lung cancer. 
Gene expression profiling through bulk RNA-sequencing and single-cell RNA-sequencing 
indicated enrichment of an ASCL1 gene signature in TKI tolerant residual cells and a pre-
existing subpopulation of untreated tumor cells from one PDX in our cohort. Despite the fact that 
a subset of lung adenocarcinomas are characterized by ASCL1 positivity [93], it still remains 
unclear what upstream regulators and/or pathways mediate ASCL1 expression in these LUAD 
cases. In the context of SCLC, the histone demethylase KDM5A has been shown to sustain 
ASCL1 expression through suppression of NOTCH signaling activity, highlighting an epigenetic 
mechanism underlying the maintenance of the NE differentiation state [97]. As future directions, 
we would like to determine the role of KDM5A as well as other epigenetic regulators in 
mediating ASCL1 expression and whether or not they can affect lineage transition in PDXs and 
cell lines of EGFR mutant lung cancer. Ongoing experiments are designed to overexpress 
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ASCL1 in established human cell lines, followed by functional testing including target gene 
expression, drug sensitivity and clonogenic assay. 
 
Targeting drug tolerant residual disease to delay acquired resistance. 
One of the reasons for studying mechanisms of drug tolerance is to identify drug targets to 
repress or eliminate persister cells to delay or prevent the emergence of acquired resistance. 
Based on the results from this thesis project, we identified ASCL1 as a driver of TKI tolerance in 
mutant EGFR lung cancer. Studies in SCLC have provided clear evidence that ASCL1 is a 
critical regulator of NE differentiation and required for tumor initiation and maintenance [89, 92, 
97, 98]. In addition, SCLC transformation is one of the common TKI resistance mechanisms. 
Therefore, targeting ASCL1 could be of potential use in treating patients with incomplete 
response to EGFR TKIs and upregulation of ASCL1 in residual cells. As ASCL1 functions as a 
transcription factor, developing its small molecule inhibitor is proved to be challenging. 
Alternative strategies include identifying druggable targets among upstream regulators and 
downstream gene targets of ASCL1. One canonical target gene regulated by ASCL1 encodes 
the anti-apoptotic protein BCL2, for which BH3-mimetic small molecule venetoclax has been 
approved to treat cancers dependent on the anti-apoptotic effects of BCL2 [115, 116]. The 
combination of EGFR TKIs and BCL2 inhibitors could be used as a follow-up treatment for 
leftover tumor cells after initial targeted therapy [45]. Another ASCL1-targeting strategy under 
development is to directly modulate its protein levels. Depending on the chemical nature of a 
gene product, it is possible to design protein degraders that target either the protein-of-interest 
(POI) itself or its binding partners that stabilize the POI. Recent genetic and chemical screening 
identified CDK2 as a stabilizer of ASCL1 protein and degradation of CDK2 by PROTAC reduced 
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